NEJM Evidence

Published January 23, 2025
NEJM Evid 2025;4(2)
DOI: 10.1056/EVIDoa2400209

ORIGINAL ARTICLE

A Proof-of-Concept Study of Ulipristal Acetate for Early Medication Abortion

Beverly Winikoff, M.D., M.P.H.,[1] Manuel Bousiéguez, M.B.A.,[1] Jorge Salmerón, M.D., D.Sc.,[2] Karina Robles-Rivera, M.D., M.S.H.,[3] Sonia Hernández-Salazar, M.Sc.,[2] Angélica Martínez-Huitrón, M.D., M.P.H.,[4] María Laura García-Martínez, M.D.,[5] Lucía Aguirre-Antonio, M.D.,[5] and Ilana G. Dzuba, M.H.S.[1]

Abstract

BACKGROUND The current regimen for early medication abortion in many countries is mifepristone and misoprostol, but mifepristone is relatively expensive and limited in many regions. Ulipristal acetate, with a similar chemical profile, might be an alternative. This proof-of-concept study evaluated ulipristal acetate and misoprostol for medication abortion through 63 days of gestation.

ellaOne is abortifacient

Fig. 1a

METHODS We conducted a two-stage clinical study to choose an effective and acceptable ulipristal–misoprostol regimen. First, we undertook a dose-finding study. Sixty-six participants were randomly assigned to either 60 mg or 90 mg of oral ulipristal, followed by 800 μg of buccal misoprostol. Because the two groups had similar efficacy and safety profiles, we opted for the 60-mg ulipristal dose for an open-label study with 100 additional participants, resulting in a total of 133 participants using the same regimen. To evaluate acceptability, we applied a structured questionnaire at the end of the follow-up visit.

RESULTS Pregnancy termination occurred with the combination of oral ulipristal 60 mg and buccal misoprostol 800 μg in 129 out of 133, or 97.0%, (95% confidence interval [CI], 94.1 to 99.9%), of participants. Among those for whom this regimen did not result in pregnancy termination, one participant had a completion with sharp curettage, two received manual vacuum aspiration, and one underwent a repeat medication abortion with misoprostol alone. Side effects included chills (77.4%; 95% CI, 70.3 to 84.5%), diarrhea (66.9%; 95% CI, 59.0 to 74.8%), and nausea (48.1%; 95% CI, 39.7 to 56.5%). No serious adverse events were reported. The regimen was deemed "acceptable" or "highly acceptable" by 97.7% (95% CI, 95.2 to 100.0%) of participants.

CONCLUSIONS This study suggests that ulipristal acetate followed by misoprostol is an effective and acceptable medication abortion regimen with no reported serious adverse events. (This project is supported by the OPTions Initiative. The study registered as ISRCTN35625202.)

ellaOne 2 cps: 97% abortion till 9 g.w.

Fig. 1b

emergency contraception

drugs

IUDs

after

unprotected intercourse
in the fertile period of the cycle

Fig. 1c


FSH
LH
pituitary
gland
ovarian
follicles
corpus luteum
5,4,3,2,1,0
estrogens
progesterone
0
14
28
endometrial
gland
endometrium

Fig. 2

CI-1

ella®
ulipristal acetate

FDA Reproductive Health Drugs Advisory Committee
June 17, 2010

HRA Pharma

Fig. 3

CONCEPTION

CM-15

The Fertile Window

David Archer, MD

Probability of conception on specific days near the day of ovulation



Figure 2 from *Wilcox et al. 1995*

The bars represent probabilities calculated from data on 129 menstrual cycles in which sexual intercourse was recorded to have occurred on only a single day during the 6-day interval ending on the day of ovulation (day 0). The solid line shows daily probabilities based on all 625 cycles, as estimated by the statistical model.

Wilcox, et al. *New Engl J Med.* 1995;33(23):1517-1521.

Fig. 4

INTERCOURSES

CM-16

Frequency of Intercourse

Proportion of contracepting women who have intercourse on a given day of the menstrual cycle, relative to the day of ovulation



Figure 1 from *Wilcox et al. 2004*

Dashed line shows mean value for each day, while the dark solid line shows the 3-day moving average (each data point representing the mid-point of a 3-day span). The 6 fertile days are shaded, with the day of ovulation (0) marked by the thin vertical line. The intercourse line represents the overall mean frequency of intercourse on non-bleeding days (0.290). n = 68 women, 171 cycles.

Wilcox, et al. *Human Reprod,* 2004;19(7):1539-1543.

Fig. 5

Distribution of UPIs
Study 509 – mITT Population

UNPROTECTED

FIGURE 3.1 - HISTOGRAM OF DAYS FROM FIRST DAY OF LAST MENSTRUAL PERIOD TO THE UNPROTECTED INTERCOURSE (mITT)



Fig. 6

Progesterone → → immune tolerance



- Glycodelin
- Th-2>>Th-1
- PIBF → IL-4
- EPF ovarian (Embryo Factor)
- ↓
- I- kβ anti NF-kβ
- p-NKc → u-NKc

hCG embryo

endometrium

END-1

MMP

Endothelin-1 --- Enkefalinase

Fig. 7


PAF
Platelet Activating
entro 48 h
Immuno
IF
suppressive
23 23
modulates
maternal
immune
defenses
EPF
Early Pregnancy
immediately

Fig. 8





constant volume



5 + 53



8 + 99

Fig. 9



Fig. 10



progesterone

Fig. 11


GERMINAL EPITHELIUM
TUNICA ALBUGINEA
EPITHELIAL CORD STREAMING DOWNWARD TO SURROUND OVA
CORTEX
PRIMORDIAL OVUM
INFANT OVARY
OVUM
NUCLEUS
ZONA PELLUCIDA
CORONA RADIATA
CUMULUS OÖPHORUS
GRANULOSA
THECA INTERNA
THECA EXTERNA
FLUID–FILLED FOLLICULAR CAVITY (ANTRUM)
RIPENING FOLLICLE
EPITHELIAL CORD
PRIMARY FOLLICLE
GERMINAL EPITHELIUM
BLOOD VESSELS ENTERING HILUS
HILUS CELLS
CORPUS ALBICANS
DEVELOPING FOLLICLES
MATURE FOLLICLE
CORPUS HEMORRHAGICUM (RUPTURED FOLLICLE)
DISCHARGED OVUM
CORPUS LUTEUM (EARLY)
BLOOD

Fig. 12



Fig. 13



Fig. 14



Fig. 15

Fig. 16

SPRM

Selective
Progesterone
Receptor
Modulator

Ulipristal Acetate

UPA inhibirs
Progesterone Receptors

ellaOne ®

within 120 h.s (5 days) since UPSI

(occurred in the fertile period)

Fig. 17

Ellaone® : UPA 30 mg micronized

Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non-inferiority trial and meta-analysis

Anna F Glasier, Sharon T Cameron, Paul M Fine, Susan J S Logan, William Casale, Jennifer Van Horn, Laszlo Sogor, Diana L Blithe, Bruno Scherrer, Henri Mathe, Amelie Jaspart, Andre Ulmann, Erin Gainer

Summary

Background Emergency contraception can prevent unintended pregnancies, but current methods are only effective if used as soon as possible after sexual intercourse and before ovulation. We compared the efficacy and safety of ulipristal acetate with levonorgestrel for emergency contraception.

Methods Women with regular menstrual cycles who presented to a participating family planning clinic requesting

Lancet 2010; 375: 555–62

Published Online January 29, 2010

DOI:10.1016/S0140-6736(10)60101-8

EQUIVALENT to UPA 50 mg unmicronized used in previous studies



Progesterone

Fig. 19



RU486
(Mifepristone)



ellaOne
(Ulipristal Acetate)

Phase 2/3 Efficacy Trials
Study 507*

EFFICACY

	Methods
Time window	within 72 hr of intercourse
Study sites	7 clinical sites (USA)
Design	Randomized & double blind
Treatments	UPA 50 mg + placebo 12 hr later
	LNG 0.75 mg × 2 12 hr apart
Primary efficacy endpoint	Observed pregnancy rate
Hypothesis tested	Non-inferiority UPA to LNG
Sample size for efficacy analysis	770 subjects per group



Fig. 20

0.9 vs. 5.8

expected

* Creinin, et al. *Obstet Gynecol.* 2006;108(5):1089-1097.

Trend in Pregnancy Rates Over Time
mITT Pooled Phase 3 Population
Studies 509, 513—Dose 30 mg



Fig. 21

EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Site-wide search GO

Advanced document search

Home | Find medicine | Human regulatory | Veterinary regulatory | Committees | News & events | Partners & networks | About us

- Human medicines
  - European public assessment reports
  - Patient safety
  - Pending EC decisions
  - Withdrawn applications
  - Paediatrics
  - Rare disease designations
  - Medicines under evaluation
  - Medicines for use outside the EU
  - Referrals

Home ▸ Find medicine ▸ Human medicines

ellaOne

ulipristal acetate

Email Print Help Share

About | Authorisation details | Product information | Assessment history

« Previous tab Next tab »

Product information

22/02/2018 ellaOne -EMEA/H/C/001027 -N/0047

Name	Language	First published	Last updated
ellaOne: EPAR - Product Information	EN = English GO	13/11/2009	23/09/2024

AUTHORISED
This medicine is approved for use in the European Union

ellaOne RSS feed

News

- Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 November 2014 (21/11/2014)
- EMA recommends availability of

ANNEX I - Summary of Product Characteristics - 5.1 Pharmacodynamic properties

Ulipristal acetate is an orally-active synthetic selective progesterone receptor modulator which acts via high-affinity binding to the human progesterone receptor. When used for EC the mechanism of action is inhibition or delay of ovulation (page 8)

Fig. 22

EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Site-wide search GO

Advanced document search

Home | Find medicine | Human regulatory | Veterinary regulatory | Committees | News & events | Partners & networks | About us

- Human medicines
  - European public assessment reports
  - Patient safety
  - Pending EC decisions
  - Withdrawn applications
  - Paediatrics
  - Rare disease designations
  - Medicines under evaluation
  - Medicines for use outside the EU
  - Referrals

Home ▸ Find medicine ▸ Human medicines

ellaOne

ulipristal acetate

Email Print Help Share

About | Authorisation details | Product information | Assessment history

« Previous tab Next tab »

Product information

22/02/2018 ellaOne -EMEA/H/C/001027 -N/0047

Name	Language	First published	Last updated
ellaOne: EPAR - Product Information	EN = English GO	13/11/2009	23/09/2024

AUTHORISED
This medicine is approved for use in the European Union

ellaOne RSS feed

News

- Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 November 2014 (21/11/2014)
- EMA recommends availability of

ANNEX III - B. PACKAGE LEAFLET - 1. What ellaOne is and what it is used for

How ellaOne works --- ellaOne contains the substance ulipristal acetate which acts by modifying the activity of the natural hormone progesterone which is necessary for ovulation to occur. As a result, ellaOne works by postponing ovulation (page 39)

Fig. 23

human reproduction ORIGINAL ARTICLE *Fertility control*

HRA Study 511

TITLE

Immediate pre-ovulatory administration of 30 mg ulipristal acetate significantly delays follicular rupture

V. Brache [1,*], L. Cochon [1], C. Jesam [2], R. Maldonado [2], A.M. Salvatierra [2], D.P. Levy [3], E. Gainer [3], and H.B. Croxatto [4]

[1]PROFAMILIA, Nicolas de Ovando & Calle 16, Santo Domingo 10401, Dominican Republic [2]Instituto Chileno de Medicina Reproductiva, Santiago, Chile [3]HRA Pharma, 75003 Paris, France [4]Laboratorio de Inmunología de la Reproducción, Universidad de Santiago de Chile y Centro para el Desarrollo de Nanociencia y Nanotecnología-CEDENNA, Santiago, Chile

*Correspondence address. Tel: +1-809-681-8357; E-mail: biomedica@codetel.net.do

Submitted on December 9, 2009; resubmitted on May 11, 2010; accepted on May 25, 2010

ABSTRACT

BACKGROUND: Current methods of hormonal emergency contraception (EC) are ineffective in preventing follicular rupture when administered in the advanced pre-ovulatory phase. This study was designed to determine the capacity of ulipristal acetate (UPA), a selective progesterone receptor modulator developed for EC, to block follicular rupture when administered with a follicle of ≥18 mm.

METHODS: This was a double-blind, crossover, randomized, placebo-controlled study. Thirty-five women contributed with UPA (30 mg. oral) and a placebo cycle. Serial blood sampling for luteinizing hormone (LH), estradiol and progesterone measurements and follicular monitoring by ultrasound were performed before and for 5 days following treatment. Follicular rupture inhibition was assessed in the overall study population and in subgroups of women stratified by when treatment was administered in relation to LH levels (before the onset of the LH surge, after the onset of the surge but before the LH peak or after the LH peak).

RESULTS: Follicular rupture failed to occur for at least 5 days following UPA administration in 20/34 cycles [59%; 95% confidence interval (CI) (40.7–75.4%)], whereas rupture took place in all cycles within 5 days of placebo intake. When UPA was administered before the onset of the LH surge, or after the onset but before the LH peak, follicle rupture had not occurred within 5 days in 8/8 (100%) and 11/14 [78.6%; 95% CI (49.2–95.3)] cycles, respectively. In contrast, when UPA was given after the LH peak, follicle rupture inhibition was only observed in 1/12 [8.3%; 95% CI (0.2–38.5)] cycles.

CONCLUSIONS: This study demonstrates that UPA can significantly delay follicular rupture when given immediately before ovulation. This new generation EC compound could possibly prevent pregnancy when administered in the advanced follicular phase, even if LH levels have already begun to rise, a time when levonorgestrel EC is no longer effective in inhibiting ovulation.
NCT01107093: Comparison of CDB-2914 versus placebo in the prevention of follicular rupture post-LH surge.

Key words: ulipristal acetate / emergency contraception / follicular rupture / LH surge

Fig. 24

gen–progestogen combinations administered well before the onset of the LH surge exert inhibitory effects on ovulation via shunting of the LH surge, but they do not significantly delay or inhibit follicular rupture when administered in the advanced pre-ovulatory phase (Croxatto *et al.*, 2001; Gemzell-Danielsson and Marions, 2004; Novikova *et al.*, 2007). In two studies, conducted by the same investigators, using the same design and same conditions of treatment (administration when lead follicle has reached 18 mm in diameter), LNG-EC inhibited dominant follicular rupture for 5 days after treatment in only 2/17 (12%) and 5/31 (16%) women, respectively (Croxatto *et al.*, 2004; Massai *et al.*, 2007). The results from these two trials were very similar and, when combined, this resulted in follicle rupture inhibition in 7/48 women (14.6%) of the LNG studied cycles as compared with 20/34 (58.8%) women with UPA. When comparing the proportions of follicular rupture inhibition at 5 days of treatment using a Fisher exact test, the difference between LNG and UPA is significant ($P < 0.0001$).

CONCLUSIONS

In summary, this study provides mechanistic evidence to explain how UPA could be more effective in preventing pregnancy than current reference EC methods. It suggests that UPA is able to inhibit or significantly delay follicular rupture for over 5 days if given immediately before ovulation by postponing the LH peak.

Fig. 25

Table I LH status and mean LH levels (U/l) in women at time of treatment with UPA or placebo in a study of the capacity of UPA to block follicular rupture.

	UPA		Placebo	
	n (1st/2nd cycle)	LH (Mean ± SD)	*n* (1st/2nd cycle)	LH (Mean ± SD)
Treatment before LH surge onset	8 (5/3)	4.1 ± 1.8	12 (6/6)	4.8 ± 1.7
Treatment after LH surge onset but before LH peak	14 (7/7)	10.0 ± 2.6	6 (2/4)	11.8 ± 2.3
Treatment after LH peak	12 (5/7)	54.8 ± 21.3	16 (9/7)	47.8 ± 23.5

1

Table II Inhibition of follicular rupture observed 5 days after treatment administration.

Treatment	UPA *n* (%)	
Placebo *n* (%)	No	Yes
No	14 (41.2%)	20 (58.8%)
Yes	0 (0.0%)	0 (0.0%)
McNemar's test		
Statistic (DF)	20.0000 (1)	
P-value	<0.0001	

2

Table III Inhibition of follicular rupture at 5 days after treatment administration, stratified by LH status at time of treatment.

	UPA *n* (%) [95% CI]	Placebo *n* (%) [95% CI]
Treatment before LH surge onset	8/8 (100%)	0/12 (0%)
Treatment after LH surge onset but before LH peak	11/14 (78.6%) [49.2–95.3]	0/6 (0%)
Treatment after LH peak	1/12 (8.3%) [0.2–38.5]	0/16 (0%)

of these cycles, the treatment had been administered on the day of LH peak. Follicular rupture was delayed by 5–10 days or did not occur in the remaining 67.6% (23/34) of cycles.

When treatment was given before the LH peak, the mean time that elapsed from treatment intake to follicle rupture was still significantly longer in UPA cycles (6.85 ± 1.42 days) than in placebo cycles (3.53 ± 0.80 days) ($P = 0.0001$), however, when UPA was given at the time of the LH peak, the time elapsed to rupture was similar to placebo (1.54 ± 0.52 versus 1.31 ± 0.48).

3

Brache

Follicular growth and outcome

Table IV shows the final outcome of the follicle at the end of the menstrual cycle. Of the 20 UPA cycles in which follicular ru[illegible] not occurred by Day 5, 15 women had a delayed ruptur[illegible] and the mean follicular diameter prior to rupture [illegible].3 ± 2.8 mm) than the one observed in the [illegible] 20.5 ± 2.5 mm) or in the UPA cycles (19.8 ± 2.5[illegible]d within 5 days of treatment. Two women had a[illegible]h luteiniza-tion occurring prior to delayed ru[illegible]0 post-UPA (progesterone = 12.8 and 60.7 nmo[illegible]ple pre-rupture), and in three women a luteinized unr[illegible]e was documented. These follicles measured a maximum [illegible], 30.0 and 22.0 mm, but all had decreased to <25 mm diameter by the onset of menses.

RESULTS

Hormones

An immediate drop in LH levels was observed on the day following UPA

Figure 2

Table IV administr

Follicle rupt post-treatm

Follicle rupt days post-t

Luteinizatio

Luteinized

Fig. 26

Treatment after LH peak	12 (5/7)

Table II Inhibition of follicular rupture observed 5 days after treatment administration.

Treatment	UPA *n* (%)	
Placebo *n* (%)	No	Yes
No	14 (41.2%)	20 (58.8%)
Yes	0 (0.0%)	0 (0.0%)
McNemar's test		
Statistic (DF)	20.0000 (1)	
P-value	<0.0001	

1

OVERALL RESULTS

Fig. 27

2

Table III Inhibition of follicular rupture at 5 days after treatment administration, stratified by LH status at time of treatment.

	UPA *n* (%) [95% CI]	Placebo *n* (%) [95% CI]
Treatment before LH surge onset	8/8 (100%)	0/12 (0%)
Treatment after LH surge onset but before LH peak	11/14 (78.6%) [49.2–95.3]	0/6 (0%)
Treatment after LH peak	1/12 (8.3%) [0.2–38.5]	0/16 (0%)

CI, confidence interval.

anti-ovulatory UPA's effect drops from 1st to 3rd- 4th fertile day

Fig. 28

	n (1st/2nd cycle)	LH (Mean ± SD)	n (1st/2nd cycle)	LH (Mean ± SD)
	8 (5/3)	4.1 ± 1.8	12 (6/6)	4.8 ± 1.7
ore LH peak	14 (7/7)	10.0 ± 2.6	6 (2/4)	11.8 ± 2.3
	12 (5/7)	54.8 ± 21.3	16 (9/7)	47.8 ± 23.5

taken 3-4 days before ovulation UPA delays it ≅ 3 days
we are at the very start of the fertile period

3

occur in the remaining 67.6% (23/34) of cycles.

When treatment was given before the LH peak, the mean time that elapsed from treatment intake to follicle rupture was still significantly longer in UPA cycles (6.85 ± 1.42 days) than in placebo cycles (3.53 ± 0.80 days) ($P = 0.0001$), however, when UPA was given at the time of the LH peak, the time elapsed to rupture was similar to placebo (1.54 ± 0.52 versus 1.31 ± 0.48).

Brache

RESULTS

one-two days before ovulation Ulipristal is ineffective:
these are the most fertile days and ovulation occurs

strual cycle. Of the 20 UPA cycles in which follicular rupture had not occurred by Day 5, 15 women had a delayed rupture (Day 6–1

Fig. 29

The Fertile Window

David Archer, MD

Probability of conception on specific days near the day of ovulation



Figure 2 from *Wilcox et al. 1995*

The bars represent probabilities calculated from data on 129 menstrual cycles in which sexual intercourse was recorded to have occurred on only a single day during the 6-day interval ending on the day of ovulation (day 0). The solid line shows daily probabilities based on all 625 cycles, as estimated by the statistical model.

Wilcox, et al. *New Engl J Med.* 1995;33(23):1517-1521.

Fig. 30

Table III Inhibition of follicular rupture at 5 days after treatment administration, stratified by LH status at time of treatment.

	UPA *n* (%) [95% CI]		Placebo *n* (%) [95% CI]
Treatment before LH surge onset	8/8 (100%)		0/12 (0%)
Treatment after LH surge onset but before LH peak	11/14 (78.6%)	[49.2–95.3]	0/6 (0%)
Treatment after LH peak	1/12 (8.3%)	[0.2–38.5]	0/16 (0%)

CI, confidence interval.

UPA's anti-ovulatory effect drops from 1st to 3rd- 4th fertile day

Fig. 31

CE-19

Trend in Pregnancy Rates Over Time
mITT Pooled Phase 3 Population
Studies 509, 513—Dose 30 mg

Expected and observed pregnancy rates per 24-hr interval



Expected pregnancy rate 5.62%

Observed pregnancy 1.88%

the efficacy does not diminish…..

Fig. 32

Molecular and Cellular Endocrinology xxx (2017) 1–11

Contents lists available at ScienceDirect

Molecular and Cellular Endocrinology

journal homepage: www.elsevier.com/locate/mce

Ulipristal acetate administration at mid-cycle changes gene expression profiling of endometrial biopsies taken during the receptive period of the human menstrual cycle

Saúl Lira-Albarrán [a, 1], Marta Durand [a, 1], Marco F. Larrea-Schiavon [c], Leticia González [a], David Barrera [a], Claudia Vega [a], Armando Gamboa-Domínguez [b], Claudia Rangel [c], Fernando Larrea [a, *]

[a] *Departamento de Biología de la Reproducción Dr. Carlos Gual Castro, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Avenida Vasco de Quiroga No. 15, Ciudad de México 14080, México*

[b] *Departamento de Patología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Avenida Vasco de Quiroga No. 15, Ciudad de México 14080, México*

[c] *Departamento de Genómica Computacional, Instituto Nacional de Medicina Genómica, Periférico Sur No. 4809, Ciudad de México 14610, México*

Fig. 33

length. All participants were admitted to the outpatient clinic of the Institute during the first 10 days of their menstrual cycle. In the treated cycle, each woman received only one dose of 30 mg of UPA (EllaOne, donated by Laboratorios Elea México, S.A. de C.V.) during the preovulatory phase when the size of the leading follicle was ≥20 mm diameter. This time of the cycle was chosen to assure that treatment was done just previous the follicle ruptures when the probability of pregnancy is high. During both study cycles, each woman was instructed to avoid intercourse otherwise a barrier method was recommended, as well as asked to monitor for urinary

ellaOne (30mg UPA) given in the advanced pre-ovulatory phase, just when the probability of fertilization is the highest

Fig. 34

3. Results

3.1. Baseline and hormonal characteristics

The ovarian cycle and hormonal characteristics of volunteers are shown in Table S3. In all cases FR took place with no significant differences between control and UPA treated cycles. With exception of LH at mid-cycle, serum levels of P_4 across the luteal phase were similar between control and treated cycles and within the expected values for a normal ovulatory menstrual cycle.

3.2. Effects of UPA on global gene expression in endometrial samples

in every woman ovulation occurs

Fig. 35

Human Reproduction vol.15 no.5 pp.1092–1099, 2000

A single mid-follicular dose of CDB-2914, a new antiprogestin, inhibits folliculogenesis and endometrial differentiation in normally cycling women



Pamela Stratton[1,6], Beth Hartog[2], Negin Hajizadeh[1], Johann Piquion[1], Dorett Sutherland[3], Maria Merino[4], Young Jack Lee[5] and Lynnette K.Nieman[1]

[1]Pediatric and Reproductive Developmental Endocrinology Branch, National Institute of Child Health and Human Development, Building 10 Room 9D42, 10 Center Dr. MSC 1583, Bethesda, MD 20892–1583, [2]Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, George Washington University Medical Center, Washington DC, [3]Department of Nursing, Warren Grant Magnusen Clinical Center, [4]Surgical Pathology, National Cancer Institute, National Institutes of Health, and [5]Division of Epidemiology, Statistics, and Prevention, National Institute of Child Health and Human Development, Bethesda, MD 20892–1583, USA

[6]To whom correspondence should be addressed

Previous studies in women have shown that the antiprogestin mifepristone delays or inhibits folliculogenesis. The purpose of this study was to explore whether a new analogue, CDB-2914, has similar effects on folliculogenesis, ovulation, or on subsequent luteal phase endometrial mat-

suggesting that these agents compete for the endometrial progesterone receptor to antagonize progesterone action. Surprisingly, mifepristone also has significant effects when circulating progesterone concentrations are low, causing a delay or inhibition of folliculogenesis, steroidogenesis, and ovulation (Liu *et al.*, 1987; Shoupe *et al.*, 1987; Batista *et al.*, 1992b, 1994). These effects in the follicular phase may represent inhibition of oestradiol action by the mifepristone–progesterone receptor complex, independent of progesterone *per se*, as has been demonstrated *in vitro* (McDonnell *et al.*, 1994). Alternatively, mifepristone binding to the progesterone receptor in the absence of progesterone might alter availability of transcription factors available to the oestrogen receptor–ligand complex (Gronemeyer *et al.*, 1992). Although the mechanism of action is not understood, the clinical results (suppression of steroidogenesis and endometrial maturation) have been the rationale for exploring mifepristone efficacy for emergency contraception (Glasier *et al.*, 1992; Bygdeman *et al.*, 1997; WHO, 1999), and for the treatment of endome
fibroids (Kettel *et al.*, 1994; Murphy and Castella

Fig. 36

[a]All pre-treatment and treatment cycles were ovulatory.

we are in the seventh cycle day,
before the fertile period starts

control's ovulation
occurs six days later

Discussion

At mid-follicular doses of 10–100 mg, CDB-2914 caused a delay in ovulation that was greatest at the highest doses, but inhibited luteal phase endometrial maturation similarly at all doses. Thus, the threshold for altering endometrial morphology was lower than that for altering folliculogenesis, a finding that has not been reported previously after single dose follicular phase administration of an antiprogestin. The mechanism for this effect, noted

10 – 50 –100 mg di Ulipristal (ellaOne 30 mg is equivalent to 50)
lead to ovulation delay increasing with the higher doses

exposure. As progesterone is not thought to be critical to the endometrium prior to ovulation, it is possible that one mechanism by which CDB-2914 might exert such an effect might be

Fig. 37

	n (1st/2nd cycle)	LH (mean ± SD)	n (1st/2nd cycle)	LH (mean ± SD)
	8 (5/3)	4.1 ± 1.8	12 (6/6)	4.8 ± 1.7
re LH peak	14 (7/7)	10.0 ± 2.6	6 (2/4)	11.8 ± 2.3
	12 (5/7)	54.8 ± 21.3	16 (9/7)	47.8 ± 23.5

upture observed 5 days

%)

%)

(1)

rupture at 5 days after

of these cycles, the treatment had been administered on the day of LH peak. Follicular rupture was delayed by 5–10 days or did not occur in the remaining 67.6% (23/34) of cycles.

When treatment was given before the LH peak, the mean time that elapsed from treatment intake to follicle rupture was still significantly longer in UPA cycles (6.85 ± 1.42 days) than in placebo cycles (3.53 ± 0.80 days) ($P = 0.0001$), however, when UPA was given at the time of the LH peak, the time elapsed to rupture was similar to placebo (1.54 ± 0.52 versus 1.31 ± 0.48).

Brache

RESULTS

One-two days before ovulation Ulipristal is ineffective.
These are the most fertile days in the cycle and ovulation occurs.

occurred by Day 5, 15 women had a delayed rupture (Day 6–10) and the mean follicular diameter prior to rupture was larger (24

Fig. 38

ELSEVIER

Contraception

Contraception 87 (2013) 300–308

Review article

Emergency contraception — mechanisms of action

Kristina Gemzell-Danielsson*, Cecilia Berger, P.G.L. Lalitkumar

Department of Women's and Children's Health, Division of Obstetrics and Gynecology, Karolinska Institutet/ Karolinska University Hospital, S-171 76 Stockholm, Sweden

Received 8 July 2012; accepted 20 August 2012

Abstract

Concerns regarding the mechanisms of action of emergency contraception (EC) create major barriers to widespread use and could also lead to incorrect use of EC and overestimation of its effectiveness. While the copper intrauterine device (Cu-IUD) is the most effective method available for EC, the hormonal methods are frequently considered to be more convenient and acceptable. Today, the most commonly used method for hormonal EC is levonorgestrel (LNG). More recently, the progesterone receptor modulator ulipristal acetate (UPA) has been shown to be more effective than LNG to prevent an unwanted pregnancy. The main mechanism of action of both LNG and UPA for EC is delaying or inhibiting ovulation. However, UPA appears to have a direct inhibitory effect on follicular rupture which allows it to be effective even when administered shortly before ovulation, a time period when use of LNG is no longer effective.

Gemzell-Danielsson and Lalitkumar
Karolinska Institute

Fig. 39

In a series of clinical trials, the effect of UPA at different follicular diameters and temporal relation to the LH peak and ovulation was studied [62,63]. When given prior to the LH rise, UPA inhibited 100% of follicular ruptures. When UPA was administered when the size of the leading follicle was ≥18 mm, follicular rupture failed to occur within 5 to 6 days following treatment in 44% to 59%. Even on the day of the LH peak, UPA could delay ovulation for 24 to 48 h after administration [62]. Taken together, these studies demonstrate that UPA may have a direct inhibitory effect on follicular rupture. This allows

[62] is Brache: UPA behaves exactly as the placebo at LH peak

ovulation when LH has already started to rise, a time when LNG is no longer effective.

Pag. 302 – Gemzell-Danielsson e Lalitkumar
Karolinska Institute

Fig. 40

Contents lists available at SciVerse ScienceDirect

Best Practice & Research Clinical Endocrinology & Metabolism

journal homepage: www.elsevier.com/locate/beem

9

Emergency contraception

P.G.L. Lalitkumar, PhD, Senior Researcher in Obstetrics and Gynecology, Cecilia Berger, MD, Resident doctor in Obstetrics and Gynecology, Kristina Gemzell-Danielsson, MD, PhD, Professor *

Department of Women's and Children's Health, Division of Obstetrics and Gynecology, Karolinska Institutet/WHO-Collaborating Center, C1:05, Karolinska University Hospital, S-171 76 Stockholm, Sweden

Lalitkumar e Gemzell-Danielsson
Karolinska Institute

Fig. 41

The effect of mifepristone used for EC is dependent on the dose given and the time of treatment during the menstrual cycle. Mifepristone administered during the follicular phase delays or inhibits ovulation.[23,24] While a single high dose of mifepristone (200 mg) taken on LH + 2 has been shown to prevent endometrial receptivity and embryo implantation[25] low doses such as used for EC have no or minor effect on endometrial receptivity markers[26] and are not effective to prevent pregnancy.[27]

UPA

Given prior to the LH rise UPA inhibited 100% of follicular ruptures.[29] When UPA was administered when the size of the leading follicle was ≥18 mm, follicular rupture failed to occur within 5–6 days following treatment in 44–59%. Even on the day of the LH peak, UPA could delay ovulation for 24–48 h after administration.[29] These results indicate that UPA may have a direct inhibitory effect on follicular rupture which allows UPA to be effective even when administered before ovulation when LH has already started to rise, a time when LNG is no longer effective. The effect of UPA on the endometrium has also been demonstrated to be dose-dependent. Treatment with 10–100 mg UPA resulted in inhibit[illegible] histological maturation with the highest dose, while the effect of lower doses equivalent to the 30 mg used for EC were similar to that of placebo.[30]

[29] is Brache: UPA behaves exactly as the placebo at LH peak

Pag. 93 – Lalitkumar e Gemzell-Danielsson

Karolinska Institute

Fig. 42

HRA2914-506

Human Reproduction vol.15 no.5 pp.1092–1099, 2000

A single mid-follicular dose of CDB-2914, a new antiprogestin, inhibits folliculogenesis and endometrial differentiation in normally cycling women



Pamela Stratton[1,6], Beth Hartog[2], Negin Hajizadeh[1], Johann Piquion[1], Dorett Sutherland[3], Maria Merino[4], Young Jack Lee[5] and Lynnette K.Nieman[1]

[1]Pediatric and Reproductive Developmental Endocrinology Branch, National Institute of Child Health and Human Development, Building 10 Room 9D42, 10 Center Dr. MSC 1583, Bethesda, MD 20892–1583, [2]Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, George Washington University Medical Center, Washington DC, [3]Department of Nursing, Warren Grant Magnusen Clinical Center, [4]Surgical Pathology, National Cancer Institute, National Institutes of Health, and [5]Division of Epidemiology, Statistics, and Prevention, National Institute of Child Health and Human Development, Bethesda, MD 20892–1583, USA

[6]To whom correspondence should be addressed

Previous studies in women have shown that the antiprogestin mifepristone delays or inhibits folliculogenesis. The purpose of this study was to explore whether a new analogue, CDB-2914, has similar effects on folliculogenesis, ovulation, or on subsequent luteal phase endometrial mat-

suggesting that these agents compete for the endometrial progesterone receptor to antagonize progesterone action. Surprisingly, mifepristone also has significant effects when circulating progesterone concentrations are low, causing a delay or inhibition of folliculogenesis, steroidogenesis, and ovulation (Liu *et al.*, 1987; Shoupe *et al.*, 1987; Batista *et al.*, 1992b, 1994). These effects in the follicular phase may represent inhibition of oestradiol action by the mifepristone–progesterone receptor complex, independent of progesterone *per se*, as has been demonstrated *in vitro* (McDonnell *et al.*, 1994). Alternatively, mifepristone binding to the progesterone receptor in the absence of progesterone might alter availability of transcription factors available to the oestrogen receptor–ligand complex (Gronemeyer *et al.*, 1992). Although the mechanism of action is not understood, the clinical results (suppression of steroidogenesis and endometrial maturation) have been the rationale for exploring mifepristone efficacy for emergency contraception (Glasier *et al.*, 1992; Bygdeman *et al.*, 1997; WHO, 1999), and for the treatment of endome
fibroids (Kettel *et al.*, 1994; Murphy and Castella

Fig. 43

Table III. CDB-2914: effect on menstrual cycle length

Dose	Pre-treatment cycle length[a,b] (days ± SE)	Treatment cycle length[a,c] (days ± SE)	Post-treatment cycle length[b] (days ± SE)	Lengths of abnormal post-treatment cycles (days)
Placebo (n = 12)	30 ± 1.2 (25–37)	29 ± 1.3 (23–37)	28 ± 1.5 (23–42)	23; 42
10 mg (n = 11)	28 ± 1.0 (25–35)	29 ± 1.0 (23–35)	29 ± 1.5 (23–41)	23; 41
50 mg (n = 11)	28 ± 9.5 (25–30)	33 ± 1.5 (26–41)	28 ± 1.6 (17–34)	17
100 mg (n = 10)	28 ± 1.0 (24–35)	33 ± 1.4 (26–40)	28 ± 1.1 (23–34)	23

[a]All pre-treatment and treatment cycles were ovulatory.
[b]No difference in pre-treatment or post-treatment cycle lengths among groups.
[c]$P < 0.01$ for trend for longer treatment cycle by Jonckheere-Terpstra test.

Discussion

At mid-follicular doses of 10–100 mg, CDB-2914 caused a delay in ovulation that was greatest at the highest doses, but inhibited luteal phase endometrial maturation similarly at all doses. Thus, the threshold for altering endometrial morphology was lower than that for altering folliculogenesis, a finding that has not been reported previously after single dose follicular phase administration of an antiprogestin. The mechanism for this effect, noted long after the agent is given, might reflect a direct effect of the antiprogestin to prevent the change from proliferative to secretory endometrium, or may result from altered oestrogen exposure. As progesterone is not thought to be critical to the endometrium prior to ovulation, it is possible that one mechanism by which CDB-2914 might exert such an effect might be or oestrogen receptor β, both of which were recently described as abundant in granulosa cells of developing follicles (Revelli *et al.*, 1996; Enmark *et al.*, 1997). As frequent FSH and LH concentrations were not measured in this study, we cannot distinguish between these possibilities. Other antiprogestins are known to influence LH pulsatility, however, and this may explain the demise of the gonadotrophin-dependent dominant follicle (Permezel *et al.*, 1989). A change in LH pulsatility, amplitude and mean serum LH were not observed on the third day of a mid-follicular dose of mifepristone in a study by Liu (Liu *et al.*, 1987).

The increase in time between the LH surge and follicular collapse, and the unusual observation of two LH su[illegible] must be integrated into a model of CDB-2914 action. In

Fig. 44

[a]All pre-treatment and treatment cycles were ovulatory.

we are in the seventh cycle day, before the fertile period start

control's ovulation occurs six days later

Discussion

At mid-follicular doses of 10–100 mg, CDB-2914 caused a delay in ovulation that was greatest at the highest doses, but inhibited luteal phase endometrial maturation similarly at all doses. Thus, the threshold for altering endometrial morphology was lower than that for altering folliculogenesis, a finding that has not been reported previously after single dose follicular phase administration of an antiprogestin. The mechanism for this effect, noted

unmicronized Ulipristal 10 – 50 –100 mg (ellaOne 30 mg is equivalent to 50) inhibit equally the luteal endometrial maturation

the threshold to impair endometrial morphology is lower than that required to inhibit ovulation

Fig. 45

HRA2914-506

REPRODUCTIVE BIOLOGY

Endometrial effects of a single early luteal dose of the selective progesterone receptor modulator CDB-2914

Pamela Stratton, M.D.,[a] *Eric D. Levens, M.D.,*[a] *Beth Hartog, M.D.,*[b] *Johann Piquion, M.D.,*[a] *Qingxiang Wei, M.S.,*[a] *Maria Merino, M.D.,*[c] *and Lynnette K. Nieman, M.D.*[a]

[a] Program in Reproductive and Adult Endocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Maryland; [b] Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, George Washington University Medical Center, Washington, D.C., and [c] Laboratory of Surgical Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland

Objective: To test potential contraceptive mechanisms of the selective P receptor modulator CDB-2914 in the early luteal phase.
Design: Prospective randomized clinical trial.
Setting: Clinical research center.
Patient(s): Fifty-six women with regular cycles.
Intervention(s): Women received a single dose of CDB-2914 (10, 50, or 100 mg) or placebo given after ovulation and within 2 days of the LH surge. Four to 6 days later, a transvaginal ultrasound scan measured endometrial thickness, and an endometrial biopsy specimen was obtained.
Main Outcome Measure(s): The endometrium was evaluated by thickness and by immunohistochemical analysis for P-dependent markers; safety laboratory tests were performed, and E_2 and P levels were obtained.
Result(s): CDB-2914 caused a significant dose-dependent decrease in endometrial thickness, an increase in glandular P receptors, and a decrease in peripheral node addressins. Estradiol and P levels and menstrual cycle timing were not altered. No adverse effects were observed.
Conclusion(s): The alteration in endometrial thickness and P-dependent markers of implantation in the absence of changes in hormone levels and cycle length suggests that CDB-2914 may have contraceptive properties. (Fertil Steril® 2010;93:2035–41. ©2010 by American Society for Reproductive Medicine.)

Key Words: CDB-2914, endometrium, luteal phase, single dose, selective progesterone receptor modulators

Fig. 46

TABLE 1

Effect of CDB-2914 administration compared with placebo on outcome measures.

	Placebo (mean ± SD)	CDB-2914 (10 mg, 50 mg, 100 mg) (mean ± SD)	*P* value
Cycle length			
Baseline cycle length (d)	28.3 ± 2.2	27.8 ± 2.8	.52
Treatment cycle length (d)	28.2 ± 2.0	27.1 ± 3.2	.23
Luteal phase length during treatment (d)	12.5 ± 2.5	13.3 ± 2.4	.32
Posttreatment cycle length (d)	29.6 ± 3.5	28.2 ± 3.9	.23
Midluteal phase (treatment cycle)			
P (ng/mL)	12.5 ± 5.6	16.1 ± 8.5	.13
E_2 (pg/mL)	136.1 ± 67.6	165.3 ± 64.8	.15
Ultrasound endometrial thickness (treatment cycle)			
Baseline (mm)	10.2 ± 3.2	10.3 ± 2.3	.93
At biopsy (mm)	11.5 ± 4.1	9.7 ± 1.8	.03
Change in thickness (mm)	1.3 ± 2.3	−0.6 ± 2.2	.007

Stratton. Endometrial effects of luteal CDB-2914. Fertil Steril 2010.

a treatment cycle of 37 days; all other treatment cycles were normal length. All posttreatment cycle lengths were normal, except for two at 100 mg (20 and 21 days) and one receiving placebo (38 days). For these subjects, the subsequent cycle was of a normal length.

All 52 women who used the kit detected the LH surge in the posttreatment cycle. Of the other four, one was pregnant (10 mg) and the other three had received placebo. Of the latter three, basal body temperature was biphasic in the one woman who provided information. Eight of 56 women had inadequate information to judge corpus luteum function: four did not have a P measurement (three receiving placebo and one

tecture consistent with endometrial hyperplasia. Results of a follow-up luteal phase biopsy performed 2 months after treatment noted only stromal glandular dyssynchrony.

Baseline treatment cycle endometrial thickness was similar between groups (Table 1). The endometrial thickness on the day of biopsy ranged as follows: placebo: 5.8 to 18.7 mm; 10 mg: 8.4 to 12.6 mm; 50 mg: 6.1 to 11.7 mm; and 100 mg: 5.9 to 12.6 mm. There was a significant reduction in endometrial thickness among those subjects receiving CDB-2914 (10, 50, or 100 mg) compared with those receiving placebo (Table 1).

Fig. 47

± 3.2	10.3 ± 2.3	.93
± 4.1	9.7 ± 1.8	.03
± 2.3		

ellaOne has been taken just after ovulation, endometrial U.S. 4 - 6 days later

significant reduction in endometrial thickness after unmicronized Ulipristal 10 – 50 –100 mg (ellaOne is equivalent to 50 mg)

Baseline treatment cycle endometrial thickness was similar between groups (Table 1). The endometrial thickness on the day of biopsy ranged as follows: placebo: 5.8 to 18.7 mm; 10 mg: 8.4 to 12.6 mm; 50 mg: 6.1 to 11.7 mm; and 100 mg: 5.9 to 12.6 mm. There was a significant reduction in endometrial thickness among those subjects receiving CDB-2914 (10, 50, or 100 mg) compared with those receiving placebo (Table 1).

Fig. 48

mL (one at 10
gth was normal
cycle length of

5 had sufficient
of biopsy cal-
l biopsy speci-
100 mg: 4)
ay of >2 days;
on the day of
14 (50 or 100
ed endometrial
dds ratio: 2.2;
. Additionally,
e of increasing
ating doses of

(Fisher's exact test; $P=.02$) with those receiving higher CDB-2914 doses demonstrating greater staining as evidenced by immunohistochemical analysis (Jonckheere-Terpstra test; $P=.01$). For example, 8 of 15 specimens (53%) in

UPA 50 mg unmicronized (ellaOne equivalent), taken just after ovulation, reduces the markers of endometrial receptivity

the glands or stroma (data not shown). MECA-79 staining was similar in the placebo (median: 3.8) and 10-mg (median: 3.5) groups but was significantly reduced in the 50-mg (median: 2.1) and 100-mg groups (1.5) ($P<.001$) with a notable linear decline in the staining with increasing CDB-2914 dosage (point estimate: −0.019; 95% confidence interval: −0.023, −0.015; $P<.001$) (Fig. 1).

peripheral node-addressin

Fig. 49

early luteal phase (after ovulation)

CDB-2914 inhibited P-dependent markers of luteal phase differentiation. Both CDB-2914 and early luteal phase doses of 200 mg of mifepristone prevent the expected luteal phase decrease in glandular PR staining (1, 2, 4). CDB-2914 also was associated with decreased expression of peripheral node addressins, which are important L-selectin ligands found on the surface of endothelial cells. Recent studies have shown that L-selectin ligands are up-regulated during the implantation window, making the uterus more receptive to the trophoblast (17, 18).

3,2 x 273,0 mm

❖ UPA: anti-implantatiom

Fig. 50

noted above, all posttreatment laboratory values were normal.

ellaOne taken just after ovulation (endometrial biopsy 4 - 6 days later)

DISCUSSION

A single postovulatory dose of up to 100 mg of the antiproges-tin CDB-2914 significantly increased glandular PRs and decreased endometrial thickness. Treatment did not alter cor-

10 mg unmicronized UPA, equivalent to one fifth of ellaOne, have the same endometrial effects as 200 mg RU486

cycle. CDB-2914 appeared to inhibit endometrial develop-ment while sparing menstrual rhythm. The current study was the first dose-ranging study to document significant endo-metrial effects with low doses of CDB-2914 given in the early luteal phase. Similar endometrial effects have been observed among those receiving mifepristone (200 mg) (1, 3, 4); how-ever, these endometrial effects were present at lower doses (10 mg) (15). Whether there is a difference in potency between

200 mg mifepristone is the dose to terminate pregnancy

Fig. 51

early luteal phase (after ovulation)

with a single dose given in either early luteal or midluteal phase. Whether this is a direct endometrial effect or a result of an ovarian effect is not known. Taken together, these endometrial effects in the absence of ovarian and menstrual cycle effects suggest mechanisms by which CDB-2914 might be effective as an emergency contraceptive (28).

Acknowledgments: The authors thank Dr. Negin Hajizadeh M.D., for her assistance in data management and Dorett Sutherland, R.N., for her assistance with scheduling and patient care.

203,2 x 273,0 mm

❖ **UPA: anti-implantation**

Fig. 52

Human Reproduction Vol.18, No.9 pp.1820–1827, 2003 DOI: 10.1093/humrep/deg342

Luteal phase dose–response relationships of the antiprogestin CDB-2914 in normally cycling women*

Maureen D.Passaro[1,5], Johann Piquion[1,6], Nancy Mullen[2,7], Dorette Sutherland[2], Suoping Zhai[3], William D.Figg[3], Richard Blye[4] and Lynnette K.Nieman[1]

[1]Pediatric and Reproductive Endocrinology Branch, National Institute of Child Health and Human Development, [2]Department of Nursing, Warren Grant Magnuson Clinical Center, [3]Molecular Pharmacology Section, National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892 and [4]Contraception & Reproductive Health Branch, National Institute of Child Health and Human Development, Executive Bldg, Rm 8B07, 6100 Executive Blvd MSC 7510, Bethesda, MD 20892-7510, USA,

[5]Present address: 650 Pennsylvania Ave SE, Suite 50, Washington, DC 20003, USA.
[6]Current address: 12 Wexford Glenn, Pittsford, NY 14534, USA.
[7]Present address: 3 Chevy Chase Circle, Chevy Chase, MD 20815, USA

[8]To whom correspondence should be addressed. E-mail: NiemanL@nih.gov

Fig. 53

BACKGROUND: Progesterone receptor modulators have potential therapeutic use in progesterone-dependent conditions such as endometriosis, fibroids and induction of labour. The synthetic steroid CDB-2914 binds to the progesterone and glucocorticoid receptors. In animals it has antiprogestational activity at doses 50-fold less than those required for antiglucocorticoid effects. METHODS AND RESULTS: We evaluated the biological activity, blood levels and safety of CDB-2914 at escalating single doses, in 36 normally cycling women at mid-luteal phase. CDB-2914 at doses of 1–100 mg did not change luteal phase length, but after 200 mg, all women had early endometrial bleeding. Four women with early menses had concurrent functional luteolysis (one at 10, 50, 100 and 200 mg). There were no biochemical or clinical signs of toxicity, and no effect on urinary cortisol or circulating thyroxine, prolactin, adrenocorticotrophic hormone or renin levels. Higher serum equivalents of CDB-2914 were observed by radioimmunoassay than by high performance liquid chromatography detection, indicating a considerable contribution of metabolites. CONCLUSIONS: Mid-luteal administration of CDB-2914 antagonizes progesterone action on the endometrium, in a dose-dependent fashion, without apparent antiglucocorticoid effects. Further

mid-luteal phase (implantation window)

Table II. Effects of CDB-2914 on bleeding pattern and luteal phase length

Dose	Women with early bleeding (no./total)	Length of luteal phase (days)	Cycle length (days)
Placebo	0/5	13.4 ± 0.5	27.2 ± 1.5
1 mg	1/6	13.7 ± 1.0	27.0 ± 1.1
10 mg	2/6	13.5 ± 1.1	29.2 ± 0.9
50 mg	3/6	11.8 ± 1.2	27.3 ± 2.0
100 mg	2/7	13.1 ± 1.2	27.6 ± 0.8
200 mg	6/6	9.7 ± 0.3*	23.8 ± 1.5**

ellaOne equivalent

*

*$P < 0.02$ 200 mg compared with placebo, 1 mg, 10 mg, 100 mg groups; $P = 0.13$ versus 50 mg.

**$P < 0.04$ compared with 10 mg and 100 mg groups.

Fig. 54

∗ **unmicronized UPA200 mg are equivalent to 4 ellaOne**

oral dose of 200 mg. Early endometrial sloughing occurred in most women despite luteal phase progesterone levels, indicating a direct action on the endometrium, rather than an indirect action on the ovary to reduce steroid production. However, concurrent functional luteolysis was observed in a few women who had early bleeding.

The endometrial effects of CDB-2914 are similar to those of mifepristone, which induces uterine bleeding within 72 h of mid-luteal administration by acting directly on the endometrium to inhibit progesterone activity (Schaison *et al.*, 1985; Shoupe *et al.*, 1987; Garzo *et al.*, 1988; Nieman and Loriaux, 1988). The data from this study suggest that CDB-2914 and mifepristone are roughly equivalent in this regard. At 200 mg (~3–4 mg/kg), CDB-2914 consistently caused early endometrial bleeding. By contrast, the minimal luteal phase dose

Fig. 55

Molecular and Cellular Endocrinology xxx (2017) 1–11

Contents lists available at ScienceDirect

Molecular and Cellular Endocrinology

journal homepage: www.elsevier.com/locate/mce

Ulipristal acetate administration at mid-cycle changes gene expression profiling of endometrial biopsies taken during the receptive period of the human menstrual cycle

Saúl Lira-Albarrán [a, 1], Marta Durand [a, 1], Marco F. Larrea-Schiavon [c], Leticia González [a], David Barrera [a], Claudia Vega [a], Armando Gamboa-Domínguez [b], Claudia Rangel [c], Fernando Larrea [a, *]

[a] *Departamento de Biología de la Reproducción Dr. Carlos Gual Castro, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Avenida Vasco de Quiroga No. 15, Ciudad de México 14080, México*

[b] *Departamento de Patología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Avenida Vasco de Quiroga No. 15, Ciudad de México 14080, México*

[c] *Departamento de Genómica Computacional, Instituto Nacional de Medicina Genómica, Periférico Sur No. 4809, Ciudad de México 14610, México*

Fig. 56

ellaOne preovulatory (in the most fertile days)

2000, 2010), indicate that part of its contraceptive effects, particularly in those women remaining ovulatory after treatment, might involve the endometrium. This statement contrasts to that of international scientific societies ensuring that the main contraceptive action of UPA is ovulation impairment without affecting implantation (Rosato et al., 2015). In view of this controversy and on the relative lack of information of the effects of UPA on endometrium, especially under *in vivo* conditions, herein we investigated the effects of a single administration of 30 mg of UPA to women just before FR, when follicular diameter reached ≥20 mm, on the global gene expression profile in endometrial biopsies taken during the window of implantation, seven days after the LH peak (LH+7). Serum pituitary and ovarian hormones were measured and

evaluation of the expression of 1183 genes in the mid-luteal phase

Fig. 57

3. Results

3.1. Baseline and hormonal characteristics

The ovarian cycle and hormonal characteristics of volunteers are shown in Table S3. In all cases FR took place with no significant differences between control and UPA treated cycles. With exception of LH at mid-cycle, serum levels of P_4 across the luteal phase were similar between control and treated cycles and within the expected values for a normal ovulatory menstrual cycle.

3.2. Effects of UPA on global gene expression in endometrial samples

all women had a normal ovulation (FR = follicular rupture)

Fig. 58

3.2.2.3. Activation state of canonical pathways and bio-functions by ingenuity pathway analysis (IPA). Ingenuity pathway analysis of the list of differentially expressed genes in UPA treated cycles *versus* control cycles showed that canonical pathways, such as acute phase response, STAT3, integrin, IL-6 and VEGF signaling pathways were among the top down-regulated (Table 3). These results agreed with those identified by different approaches, such as FatiGO and GSEA since, the majority of these canonical pathways were associated with biological processes involved in inflammatory responses.

In terms of bio-functions: cell survival, movement and cell invasion and those related with chemotaxis, adhesion, formation of gland were among those with a major negative activation z-score and predicted as decreased (Table 4).

functions indispensable for nidation inactivated

Fig. 59

3.2.2.4. Molecule activity prediction of bio-functions associated with endometrial receptivity by IPA. Since the functional analysis by REVIGO and GSEA identified regulation of inflammatory response as the most associated biological process, we performed an *in silico* analysis of MAP by querying the Ingenuity® Knowledge Base using the list of differentially expressed genes. Fig. 4 shows some of the bio-functions associated to regulation of inflammatory response. As depicted, chemotaxis of granulocytes, T lymphocytes, neutrophils, dendritic cells, macrophages, and monocytes was predicted as inhibited. This analysis agreed with the activation state of bio-functions shown in Table 4. Acute phase response signaling, Il-6 signaling and STAT3 canonical pathways were also identified within the regulation of inflammatory response (Fig. 4).

Similarly, since female pregnancy and embryo implantation were biological processes identified significantly associated in endometrium from treated cycles, we querying by IPA the activation state of the bio-function implantation. Fig. S2 shows the results of this analysis. As depicted, and based on the negative gene expression of *LIF*, *STAT3* and *IL6ST*, the bio-functions: embryo and blastocyst implantation were also predicted as inhibited.

Fig. 60

In order to identify genes affected by UPA and involved in implantation, our endometrial differentially expressed gene list of genes from UPA treated *versus* control cycles was compared with two different arrays; one called endometrial receptivity array (ERA), a customized developed array to identify the receptivity status of endometrial samples (Diaz-Gimeno et al., 2011) and with

UPA: gene expression opposite to that of endometrial receptivity array (ERA)

ERA, that 115 genes from a total of 238 genes were in common (Fig. 5A) and 34 for mifepristone from a total of 200 differentially expressed genes (Fig. 5B).

As shown in Table S9, gene expression with UPA, compared with ERA, resulted in opposite directionality in all cases. Of particular importance was the case of *PAEP*, a P_4 responsive gene and the second most up-regulated gene in ERA (FC = 31.43), represented in this study the most down-regulated gene (FC = −91.14) with the highest statistical significance (B = 22). In the case of mifepristone,

Fig. 61

antagonists (Batista et al., 1992). Ulipristal like mifepristone is considered a PR modulator; however, its effects on endometrium are poorly understood. In this study, and despite the observed normal increase of serum P_4 levels in the luteal phase, UPA showed an antiprogestin-like activity at the level of the endometrium. This observation was based on the analysis of the gene expression profile of endometrial biopsies taken on day LH+7 from ovulatory

Progesterone-Associated Endometrial Protein

endorse the antiprogestational nature of UPA on endometrium was the fact that *PAEP* expression, a P_4-dependent regulated gene and a key gene in the trophoblast to endometrium attachment process (Uchida et al., 2007), was the most down-regulated in the UPA

UPA anti-progestin

Fig. 62

ELSEVIER

Contraception 95 (2017) 586–591

Contraception

Original research article

Study of the effect of ulipristal acetate on human sperm ability to interact with tubal tissue and cumulus-oocyte-complexes☆,☆☆

Carlos Zumoffen[a,1], Matías D. Gómez-Elías[b,1], Adriana M. Caille[a], Luis Bahamondes[c], Patricia S. Cuasnicú[b], Débora J. Cohen[b], María José Munuce[a,*]

[a]*Laboratory of Reproductive Medicine, School of Biochemical and Pharmaceutical Sciences, National University of Rosario, Suipacha 531, (2000) Rosario, Argentina*
[b]*Instituto de Biología y Medicina Experimental (IBYME-CONICET), Vuelta de Obligado 2490, (1428) Buenos Aires, Argentina*
[c]*Family Planning Clinic, Department of Obstetrics and Gynecology, School of Medical Sciences, University of Campinas (UNICAMP), Caixa Postal 6181, 13084-971 Campinas, SP, Brazil*

UPA does not affect the fertilizing ability of human sperm

Abstract

Objective: Ulispristal acetate (UPA) is a selective progesterone receptor modulator widely used for emergency contraception (EC). The described main mechanism of action is by inhibiting or delaying ovulation; however, the postovulatory effects of the drug are still on debate. Therefore, the aim of this study was to determine whether UPA could interfere with human sperm fertilizing ability.

Study design: Human motile spermatozoa were incubated under capacitating conditions with or without UPA, and then used to inseminate human tubal explants, mouse cumulus-oocyte complexes and zona-free hamster eggs. The ability of UPA to interact with human sperm progesterone (P)-binding sites was investigated by incubating the cells with fluorescent-labeled P and analyzing them by fluorescence microscopy.

Results: UPA did not affect the ability of human sperm to bind to human tubal tissue explants surface or to penetrate the mouse cumulus mass and the zona-free hamster eggs. In addition, concentrations of UPA much higher than those present in the plasma of EC pill users were required to bind to human sperm P-binding sites.

Conclusions: Our study supports a lack of an agonist or antagonist action of UPA on different functional parameters associated with the fertilizing ability of human sperm.

Implications: This study provides new functional evidence supporting that the contraceptive action of UPA is not related to effects on human sperm cells, contributing to a better understanding of the mechanism of action of UPA as EC.

Fig. 63

changes on gene transcription still awaits further investigation.

The findings of the present study suggest that changes observed in gene expression in endometrial samples from women exposed to UPA are associated with a non-receptive endometrial phenotype. Based on these findings, our study provides with molecular and functional evidence the bases to support the endometrium as a target for the UPA contraceptive effects that may be of help to define the mechanisms of action of drugs used either as emergency contraceptives or for other therapeutically purposes. In addition,

non-receptive endometrium

Molecular and Cellular Endocrinology xxx (2017) 1–11

Contents lists available at ScienceDirect

Molecular and Cellular Endocrinology

journal homepage: www.elsevier.com/locate/mce

Fig. 64

Molecular and Cellular Endocrinology 476 (2018) 70–78

Contents lists available at ScienceDirect

Molecular and Cellular Endocrinology

journal homepage: www.elsevier.com/locate/mce

A single preovulatory administration of ulipristal acetate affects the decidualization process of the human endometrium during the receptive period of the menstrual cycle

Saúl Lira-Albarrán[a], Marta Durand[a], David Barrera[a], Claudia Vega[a], Rocio García Becerra[a], Lorenza Díaz[a], Janice García-Quiroz[a], Claudia Rangel[b,**], Fernando Larrea[a,*]

[a] Departamento de Biología de la Reproducción Dr. Carlos Gual Castro, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Mexico
[b] Departamento de Genómica Computacional, Instituto Nacional de Medicina Genómica, Ciudad de México, Mexico

Fig. 65

Of interest for this study was a recent publication of a meta-analysis from human transcriptomic biomarkers (Altmae et al., 2017). In this study 39 out of 57 genes recognized as putative receptive markers were common with our recently published study of UPA effects on endometrial transcriptoma (Lira-Albarran et al., 2017a). From these 39 common genes, 37 were down-regulated and two up-regulated by UPA in an opposite fashion to that observed in the meta-analysis. These data further support the anti-receptive transcriptomic effect of this selective progesterone receptor modulator in human endometrium.

ellaOne

CONCLUSION

endometrial anti-receptive trascriptomic effect

A single preovulatory administration of ulipristal acetate affects the decidualization process of the human endometrium during the receptive period of the menstrual cycle

Saúl Lira-Albarrán[a], Marta Durand[a], David Barrera[a], Claudia Vega[a], Rocio García Becerra[a], Lorenza Díaz[a], Janice García-Quiroz[a], Claudia Rangel[b,**], Fernando Larrea[a,*]

[a] Departamento de Biología de la Reproducción Dr. Carlos Gual Castro, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Mexico
[b] Departamento de Genómica Computacional, Instituto Nacional de Medicina Genómica, Ciudad de México, Mexico

Fig. 66

THE EUROPEAN JOURNAL OF CONTRACEPTION & REPRODUCTIVE HEALTH CARE
https://doi.org/10.1080/13625187.2021.1975270

Taylor & Francis
Taylor & Francis Group

RESEARCH ARTICLE

Effect of ulipristal acetate on gene expression profile in endometrial cells in culture and *in vivo* upon post-ovulatory administration in fertile women

Maripaz Jiménez Guerrero[a*], Mariana Fava[b*], Luiz F. Baccaro[b], Adriana M. Caille[c], Patricia S. Cuasnicú[d], José A. Horcajadas[a], Débora J. Cohen[d], Luis Bahamondes[b], David Cotán[a] and María José Munuce[c]

[a]SINAE, Sevilla, España; [b]Department of Obstetrics and Gynecology, Faculty of Medical Sciences, University of Campinas, Campinas, Brazil; [c]Laboratorio de Medicina Reproductiva, Facultad de Ciencias Bioquímicas y Farmacéuticas, Universidad Nacional de Rosario, Rosario, Argentina; [d]Instituto de Biología y Medicina Experimental (IBYME-CONICET), Buenos Aires, Argentina

ABSTRACT

Purpose: To analyse the effect of ulipristal acetate (UPA) as emergency contraception (EC) on the gene expression of human endometrial cell line (HEC-1A) and endometrium from fertile women treated with UPA after ovulation.

Materials and methods: HEC-1A cells were treated with UPA, and endometrial tissue from four healthy women was collected in cycles before, during and 2 months after post-ovulation pill intake. Ovulation and luteal phase were monitored, and endometrial biopsies were obtained at day LH + 7 in each cycle. In all cases, we analysed the expression profile of 192 genes associated to endometrial receptivity.

Results: We observed a significant change in total transcriptomic activity of UPA-treated HEC-1A cells compared to controls. *In vivo*, we also observed a trend to down-regulation of genes in the UPA-treated cycle that was partially restored in the post-treatment cycle. Altogether, our results supported a partially reversible effect of UPA in gene expression associated with uterine receptivity.

Conclusions: When UPA was administered after ovulation, it seems to induce a down-regulation of the main genes involved in conditioning the endometrium for implantation. This effect is partially restored two months after pill intake. The action of UPA on the endometrium for users of EC should be further investigated.

ARTICLE HISTORY
Received 14 June 2021
Revised 17 August 2021
Accepted 25 August 2021

KEYWORDS
Ulipristal acetate; emergency contraception; implantation; gene expression; endometrium

Fig. 67

Switzerland) (>4.7 ng/ml). In the treatment cycle, after a negative plasma βhCG test, we administered 30 mg of UPA (Ellaone, HRA, France) 2 days after the LH peak (LH + 2). Transvaginal ultrasound (TVU) was also performed at that

ellaOne in early luteal – ovulation documented

and endometrial thickness. The presence of follicles with diameter >15 mm followed by a 50% in size reduction was

endometrial biopsy in implantation window

Finally, at the post-treatment cycle, same procedures as in the treatment cycle were performed in order to evaluate any possible residual effect of the drug. Endometrial biopsies were collected on day LH + 7 on the natural cycles

Fig. 68

Effect of UPA treatment on gene expression profile of endometrial tissue in vivo

The age of the volunteers ranged from 32 to 36 years old, body mass index (BMI; kg/m^2) from 21 to 37 and the dur- 26 to 30 days. The UPA ovulation with the excep- eatment cycle who exhib-

192 genes associated to endometrial receptivity

Further, transcriptomic analysis of endometrial biopsies showed a significant change in total gene expression in both the treatment ($p < 0.0001$) and post-treatment ($p = 0.0001$) cycle samples compared to the pre-treatment condition without differences between the treatment and post-treatment group samples (Figure 2(A)). The increment in the histogram values denotes an overall mRNA concentration decrease of the studied genetic panel. Fold changes analysis showed a tendency to down-regulation when comparing both the treatment and post-treatment cycles with gure 2(B,C)). Thus, genes ke seem to reduce their

ellaOne down-regulates

Fig. 69

post-ovulatory ellaOne

Moreover, as far as we know, this is the first study where the reversibility of the effect on subsequent cycles was analysed. It is important to note that due to obvious ethical reasons, the profile of gene expression analysed was not obtained from an embryo-exposed endometrium.

Our results supported that when UPA is administered after ovulation, it seems to induce a down-regulation of the main genes involved in conditioning the endometrium for implantation. This effect is partially restored two months after pill intake. Nevertheless, our results cannot

down-regulates the genes that prepare the endometrium to implantation

Fig. 70

Human Reproduction, Vol.31, No.6 pp. 1200–1207, 2016
Advanced Access publication on April 6, 2016 doi:10.1093/humrep/dew055

human reproduction

ORIGINAL ARTICLE *Fertility control*

Efficacy of ulipristal acetate for emergency contraception and its effect on the subsequent bleeding pattern when administered before or after ovulation

H.W.R. Li[1,2,*], S.S.T. Lo[1,2], E.H.Y. Ng[1,3], and P.C. Ho[1,2,3]

supplemented by menstrual history and ultrasound tracking. The main outcome measure was the percentage of pregnancies prevented (PPP).

MAIN RESULTS AND THE ROLE OF CHANCE: The PPP was significantly higher in subjects who were pre-ovulatory (77.6%) compared with those who were post-ovulatory (36.4%) at the time of UPA administration ($P < 0.0001$). The observed pregnancy rate following UPA administration was significantly lower than the expected pregnancy rate only in the pre-ovulatory group ($P < 0.0001$), but not the post-ovulatory group ($P = 0.281$). The overall failure rate was 1.7% (1.4 versus 2.1% in the pre- and post-ovulatory groups, respectively). Pre-ovulatory administration of UPA resulted in a small delay (median of 3 days), whereas post-ovulatory administration resulted in a minimal advancement (median of 1 day) of the next menstruation, compared with that predicted from previous menstrual pattern. More pre-ovulatory subjects (19.1%) than post-ovulatory subjects (7.8%) had deviation of the next menses of more than 7 days ($P < 0.001$).

LIMITATIONS, REASONS FOR CAUTION: The ovulatory status of the subjects was determined based only on menstrual history and a spot sonographic finding together with serum hormonal profile at the time of recruitment.



Fig. 71

Table III Efficacy of UPA as emergency contraception when administered in pre-ovulatory versus post-ovulatory women, after excluding those subjects with further unprotected sexual intercourse in the same cycle after taking UPA ($n = 39$), those lost to follow-up ($n = 7$) and those who were subsequently suspected to be oligo-ovulatory ($n = 4$).

	Pregnancy rate, *n* (%)		Pregnancies prevented (%)[b]	*P*-values (observed versus expected, two-sided binomial test)
	Expected[a]	Observed		
Pre-ovulatory ($N = 344$)	21.2 (6.2)	4 (1.2)	81.1	<0.0001
Post-ovulatory ($N = 306$)	10.3 (3.4)	5 (1.6)	51.5	0.111
Overall ($N = 650$)	31.5 (4.9)	9 (1.4)	71.4	<0.0001

[a]Calculated after Trussell *et al.* (2003).
[b](Expected − observed)/expected.

Unreliable the number of expected pregnancies when UPA is taken in the post-ovulatory period..

- **UPSI WHEN ?**
- **in the most fertile pre-ovulatory? expected +++**
- **in the infertile luteal days ? expected zero**
- **time elapsed UPSI to UPA?**

Fig. 72

Table III Efficacy of UPA as emergency contraception when administered in pre-ovulatory versus post-ovulatory women, after excluding those subjects with further unprotected sexual intercourse in the same cycle after taking UPA ($n = 39$), those lost to follow-up ($n = 7$) and those who were subsequently suspected to be oligo-ovulatory ($n = 4$).

	Pregnancy rate, *n* (%)		Pregnancies prevented (%)[b]	*P*-values (observed versus expected, two-sided binomial test)
	Expected[a]	Observed		
Pre-ovulatory ($N = 344$)	21.2 (6.2)	4 (1.2)	81.1	<0.0001
Post-ovulatory ($N = 306$)	10.3 (3.4)	5 (1.6)	51.5	0.111
Overall ($N = 650$)	31.5 (4.9)	9 (1.4)	71.4	<0.0001

[a]Calculated after Trussell *et al.* (2003).
[b](Expected − observed)/expected.

3,4%

Li et al.: 3.4% (10.3 out of 306)

expected pregnancies **luteal** **intake percentages ≠ ≠..**

Noé et al.: 20% (7.1 out of 35)

Table 4
Comparison of the number (*n*) of women at risk of pregnancy and the contraceptive efficacy (expected/observed) according to the method used to estimate the day of ovulation in 337 cases analyzed

Method for estimating ovulatory day	Sexual intercourse		Time of LNG-EC administration				Efficacy, %
	Without risk, *n*	With risk, *n*	Preovulatory (Days −5 to −1)		Postovulatory (Day 0 or +)		
			n	Pregnancies expected/observed	*n*	Pregnancies expected/observed	
Hormones and ecography of actual cycle	215	122	87	13.2/0	35	*7.1/6**	70
LMP and length of previous cycles	168[a]	169	91	12.6/*1***	78	*13.6/3****	77

20%

Italicized values are to emphasize the differences between methods.
Fisher's Exact Test: *p=1.00; **p=.0012; ***p=.0085.
[a] Two pregnancies occurred in this group.

Fig. 73

We demonstrated that the PPP was significantly higher when UPA-EC was administered pre-ovulatory (77.6%) compared with post-ovulatory (36.4%), Although this suggested a predominantly pre-ovulatory action of UPA, the use of UPA should not be limited in real life to the 'supposed pre-ovulatory' phase of the menstrual cycle. Indeed, in practice, it is difficult to ascertain the time when a woman actually ovulates as previous studies have shown that the date of ovulation is very variable (Wilcox *et al.*, 1995). Although the observed pregnancy rate (i.e. when UPA-EC was used) was significantly lower than the expected pregnancy rate (i.e. UPSI without EC) only in the pre-ovulatory group, but not the post-ovulatory group, our sample size estimation was not based on determining a difference between the expected and observed pregnancy rate, and we might need further studies with larger sizes to prove whether a post-ovulatory effect do exist, though to a lesser extent than pre-ovulatory administration.

Fig. 74

EASY QUESTION

CM-15

The Fertile Window

anti-ovulation?

Probability of conception on specific days near the day of ovulation



Figure 2 from *Wilcox et al. 1995*

The bars represent probabilities calculated from data on 129 menstrual cycles in which sexual intercourse was recorded to have occurred on only a single day during the 6-day interval ending on the day of ovulation (day 0). The solid line shows daily probabilities based on all 625 cycles, as estimated by the statistical model.

Fig. 75

GYNECOLOGICAL ENDOCRINOLOGY

http://informahealthcare.com/gye
ISSN: 0951-3590 (print), 1473-0766 (electronic)

Gynecol Endocrinol, 2013; 29(S1): 1–14
 DOI: 10.3109/09513590.2013.774591

informa
healthcare

Emergency Contraception*

Kristina Gemzell-Danielsson[1], Thomas Rabe[2], and Linan Cheng[3]

[1]*Department of Woman and Child Health, Karolinska Institutet, WHO-centre, Karolinska University Hospital, Stockholm, Sweden,* [2]*Abteilung für Gynäkologische Endokrinologie und Fertilitätsstörungen, Universitäts-Frauenklinik Heidelberg, Heidelberg, Germany, and* [3]*Centre for Clinical Research and Training, Shanghai Institute of Planned Parenthood Research, Shanghai, China, WHO-centre*

Abstract

There have been numerous attempts to control fertility after unprotected sexual intercourse (UPSI). From very bizarre methods like the vaginal application of Coca Cola to the more serious attempts using calcium antagonists influencing fertility parameters in sperm to hormonal methods or intrauterine devices. So far, hormonal methods preventing or delaying ovulation have proved to be the most popular starting with the combination of ethinyl estradiol and levonorgestrel (LNG), known as the **Yuzpe regimen**. The first dose had to be taken within 72 hours of UPSI, a second one 12 hours later. Later on, **LNG alone**, at first in a regimen similar to the Yuzpe method (2 × 0.75 mg 12 hours apart) showed to be more successful, eventually resulting in the development of a 1.5 mg LNG pill that combined good efficacy with a high ease of use. Several efficacious and easy to use methods for emergency contraception (EC) are available on the market today with the most widely spread being LNG in a single dose of 1.5 mg

Keywords

emergency contraception, ulipristal acetate, levonorgestrel, mifepristone, "morning after pill", postcoital contraception

History

Published online 21 February 2013

Gemzell-Danielsson
Karolinska Institute

Cheng
WHO Centre

Fig. 76



gnancy rate by time after unprotected intercourse in women
pe method and levonorgestrel as emergency contraception

unmicronized UPA 50 mg
IMPAIRS the endometrium

for EC in China. The effect of mifepristone is well
depending on time of treatment during the menstrual
dose given. A variety of regimens with a single dose

micronized UPA 30 mg
DOES NOT IMPAIR

10 mg mifepristone has little or no effect on the
n [22].

A Progesterone Receptor Modulator

metabolised by the cytochrome P450 (CYP3A4).

Mechanism of action

Pag. 5

Inhibition of ovulation

UPA is a synthetic progesterone receptor modulator with oral effect which relies on a high binding affinity at the human progesterone receptor. The main mechanism consists of blocking or delaying ovulation. Clinical trials have shown that UPA depending on its dose (10–100 mg), delays the growth of the leading follicle (Graafian follicle) in the mid of the follicular phase. As a result, this leads to a delay in ovulation which was most significant in the highest doses used (50 and 100 mg micronized). This allows UPA to be effective even when administered immediately before ovulation when LH has already started to rise, a time when use of LNG or Yuzpe is too late for ovulation inhibition. In a study comparing early luteal phase treatment with placebo, 10, 50 or 100 mg unmicronized UPA a significant delay in endometrial maturation was seen in the 50 and 100 mg groups compared to the placebo and the 10 mg group upon biopsy four to six days after ovulation [36]. Treatment with UPA resulted in a significant dose-dependent decrease in endometrial thickness as well as an increase in glandular P receptors. Yet, in the doses relevant for EC use (30 mg) UPA has no significant effect on the endometrium.

Comparison the mode of action of LNG with UPA in clinical studies

Three studies investigated the mechanism of action of levonogestrel and UPA for EC:

Fig. 77

taken 12 hours apart. Follow-up was
s after the expected onset of the next
diaries were used from the time of EC use
cord adverse effects and sexual activity.
ve efficacy was evaluable in 775 of UPA
users. Pregnancies occurred in 7 (0.9%,
%, 0.8–2.6%) women, respectively. Based
day of UPSI, 85% and 69% of anticipated
y, were averted.
at le
and
ted t
–120
r old
afte
treated with a single dose of 30mg UPA.
determined by high-sensitivity urinary
otropin testing and return of menses.
1241 women were evaluated for efficacy.
ant at follow-up, for a pregnancy rate of
interval 1.4–3.1%). These results satisfy
atistical criteria for success because the
ower than both the estimated expected
edefined clinical irrelevance threshold. In
not decrease over time: pregnancy rates
2.1% (1.0–4.1%), and 1.3% (0.1–4.8%) for

unmicronized UPA 50 mg and micronized UPA 30 mg ARE EQUIVALENT

Analysis of the complete study data

Even if the complete data set of [14,37] shows only a trend in favour for UPA versus LNG, the pooled data analysis (called metaanalysis) [14] pooled with [37] shows a significant odds ratio (UPA/LNG) in favour of UPA compared to LNG (Table 4).

Contraceptive efficacy by time after UPSI (Table 4):

LNG: Slight increase up to 2.80% during 49–72 hours in [37], whereas no change over up to 5 days in [14], with low number of
6 and 97–120 hours.
ancy within 0–24 hours, 2.2%
9–72 hours. No data above 72
r 72 hours, showed a decline in
hours), over 2.1% (73–96 hours)
reasing number of subjects; no
cal relevance.

In [14] trial. there are no real difference within the first 72 hours, but no pregnancy occurred thereafter. After 72 hours the groups are small and there might be a selection bias for recruitment of subjects after 72 hours.

Due to the fact, that the metaanalysis of Glasier is in reality a combined data analysis of two different studies (even if 50 mg UPA equals 30 mg micronized UPA) (different selection criteria of subjects - see table) the final results must be interpreted with caution.

Pag. 9

Analysis of subsets of data (Table 4)

Fig. 78

GYNECOLOGICAL ENDOCRINOLOGY

http://informahealthcare.com/gye
ISSN: 0951-3590 (print), 1473-0766 (electronic)

Gynecol Endocrinol, 2014; 30(10): 685–687
 DOI: 10.3109/09513590.2014.950648

informa healthcare

ISGE STATEMENT ON EMERGENCY CONTRACEPTION

Mechanisms of action of oral emergency contraception

Kristina Gemzell-Danielsson, Cecilia Berger, and P. G. Lalitkumar

Department of Women's and Children's Health, Division of Obstetrics and Gynecology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden

Abstract

This review gives an overview of the mechanisms of action of oral emergency contraception pills (ECPs), focusing on the levonorgestrel (LNG) and ulipristal acetate (UPA) containing ECPs. *In vivo* and *in vitro* studies have addressed the effect of EC on various possible targets. Based on these studies as well as on clinical trials it is clear that the efficacy of ECPs to prevent an unintended pregnancy depends on their mechanism of action as well as on their use in relation to the fertile window. While the main effect of both available ECPs is to prevent or delay ovulation the window of action for UPA is wider than that of LNG. This provides the biological explanation for the difference observed in clinical trials and the higher efficacy of UPA. Neither LNG nor UPA impairs endometrial receptivity or embryo implantation. Correct knowledge on the mechanism of action of ECPs is important to avoid overestimating their effectiveness and to advise women on correct use.

Keywords

Emergency contraception pills, endometrium, follicular development, implantation, levonorgestrel, ovulation, ulipristal acetate

History

Received 23 July 2014
Accepted 29 July 2014
Published online 12 August 2014

Gemzell-Danielsson, Berger e Laliktumar
Karolinska Institute

Fig. 79

DOI: 10.3109/09513590.2014.950648

endometrial receptivity [27]. UPA given in early-luteal phase shows dose-dependent effects with no significant endometrial effects observed follwoing exposure to doses relevant for EC [28].

To be able to study the effect of EC on human implantation, an *in vitro* three-dimensional implantation model has been developed. In this model it has been demonstrated that LNG or UPA at EC concentrations have no effect on the human embryos or endometrial receptivity and cannot impair or prevent implantation [29]. Furthermore, LNG has shown to have no effects on pregnancy or the newborn [26,30,31]. The same is true for the more limited observational data available for UPA exposure during pregnancy (Data on file HRA-Pharma).

Gemzell-Danielsson, Berger e Laliktumar

Karolinska Institute

Fig. 80

Human Reproduction, Vol.30, No.4 pp. 800–811, 2015
Advanced Access publication on March 3, 2015 doi:10.1093/humrep/dev030

human reproduction

ORIGINAL ARTICLE *Fertility control*

Effects of ulipristal acetate on human embryo attachment and endometrial cell gene expression in an *in vitro* co-culture system

C. Berger[1,†], N.R. Boggavarapu[1,†], J. Menezes[2], P.G.L. Lalitkumar[1,†*], and K. Gemzell-Danielsson[1,†*]

[1]Department of Women's and Children's Health, Division of Obstetrics and Gynaecology, Karolinska Institutet/Karolinska University Hospital, S-171 76 Stockholm, Sweden [2]Fertilitetscentrum, Stockholm, Sweden

*Correspondence address. Tel: +46-8-51779539 (K.G.D.)/+46-704757457 (P.G.L.L.); E-mail: kristina.gemzell@ki.se (K.G.D.)/ lalit.kumar@ki.se (P.G.L.L.)

Submitted on October 3, 2014; resubmitted on November 20, 2014; accepted on January 29, 2015

STUDY QUESTION: Does ulipristal acetate (UPA) used for emergency contraception (EC) interfere with the human embryo implantation process?

SUMMARY ANSWER: UPA, at the dosage used for EC, does not affect human embryo implantation process, *in vitro*.

WHAT IS KNOWN ALREADY: A single oral dose of UPA (30 mg) [illegible]

Fig. 81



Figure 4 Six out of eleven genes suggested to be involved in endometrial receptivity in the endometrial construct, namely HAND2, OPN, HBEGF, CALCR, FGF2 and IL6 showed significant difference in their expression levels as analysed by real-time PCR on exposure with ulipristal acetate (UPA). The boxes indicate 25–75 percentile and the whiskers spread from the smallest to largest data points.

(Lalitkumar *et al.*, 2007; Meng *et al.*, 2009). Although this culture system is complex, it is now well established and has proven to be robust and reproducible. This model has also been tested and validated for the studies on human embryo attachment using LNG, mifepristone and LIF inhibitor (Lalitkumar *et al.*, 2007, 2013b; Meng *et al.*, 2009).

In this *in vitro* study, we have used a dose of UPA, equivalent to the conventional dose of UPA when used for EC. UPA at a dose of 30 mg orally has a maximum mean serum concentration (C_{max}) of 176 ± 89 ng/ml, which is observed approximately after one hour of administration (Kim and Bridgeman, 2011). However, in our study, the treatment group of cultures were continuously exposed to UPA 200 ng/ml, which is slightly higher than the observed serum concentration as it is known that the endometrial concentration of steroids is higher than the serum levels. Despite using a pharmacological dose, we do not see any significant difference in the attachment of embryos following treatment with UPA compared with controls. Also, there were no observable degenerative changes in the embryos. This further substantiates that UPA at this dose, does not compromise embryo viability nor compromise its ability to attach.

Both, *in vivo* and *in vitro* studies have shown that UPA which is a sPRM binds to progesterone receptor (Attardi *et al.* 2002, 2004). This further impacts the signal transduction mediated by PR and affects endometrial receptivity according to its binding region in the hormone response element. Not all sPRMs act in the same manner on endometrial

200 ng/ml is quite equivalent to 176 ± 89 ng/ml UPA in tissues is higher

Fig. 82

STUDY QUESTION: Does ulipristal acetate (UPA) used for emergency contraception (EC) interfere with the human embryo implantation process?

SUMMARY ANSWER: UPA, at the dosage used for EC, does not affect human embryo implantation process, *in vitro*.

WHAT IS KNOWN ALREADY: A single pre-ovulatory dose of UPA (30 mg) acts by delaying or inhibiting ovulation and is recommended as first choice among emergency contraceptive pills due to its efficacy. The compound has also been demonstrated to have a dose-dependent effect on the endometrium, which theoretically could impair endometrial receptivity but its direct action on human embryo implantation has not yet been studied.

STUDY DESIGN, SIZE, DURATION: Effect of UPA on embryo implantation process was studied in an *in vitro* endometrial construct. Human embryos were randomly added to the cultures and cultured for 5 more days with UPA ($n = 10$) or with vehicle alone ($n = 10$) to record the attachment of embryos.

PARTICIPANTS/MATERIALS, SETTING, METHODS: Endometrial biopsies were obtained from healthy, fertile women on cycle day LH+4 and stromal and epithelial cells were isolated. A three-dimensional *in vitro* endometrial co-culture system was constructed by mixing stromal cells with collagen covered with a layer of epithelial cells and cultured in progesterone containing medium until confluence. The t group received 200 ng/ml of UPA. Healthy, viable human embryos were placed on both control and treatment cultures. Five days late tures were tested for the attachment of embryos and the 3D endometrial constructs were analysed for endometrial receptivity markers by real-time PCR.

MAIN RESULTS AND THE ROLE OF CHANCE: There was no significant difference in the embryo attachment rate between the UPA treated group and the control group as 5 out of 10 human embryos exposed to UPA and 7 out of 10 embryos in the control group attached to the endometrial cell surface ($P = 0.650$). Out of 17 known receptivity genes studied here, only 2 genes, HBEGF ($P = 0.009$) and IL6 ($P = 0.025$) had a significant up-regulation and 4 genes, namely HAND2 ($P = 0.003$), OPN ($P = 0.003$), CALCR ($P = 0.016$) and FGF2 ($P = 0.023$) were down-regulated with the exposure of UPA, compared with control group.

LIMITATIONS, REASONS FOR CAUTION: This proof of concept study was conducted with a few human embryos, as their availability was limited. Although the 3D model used for this study is well established and the artificial endometrial luminal epithelium shown to express progesterone regulated markers of endometrial receptivity it is still an *in vitro* model, lacking all cell types that constitute the receptive endometrium *in vivo*.

WIDER IMPLICATIONS OF THE FINDINGS: This study provides new insights on the mechanism of action of UPA on human embryo implantation, demonstrating that UPA in a dosage used for EC does not affect embryo viability and the implantation process of embryo.

Fig. 83

European Medicines Agency
Evaluation of Medicines for Human Use

Doc.Ref.: EMEA/261787/2009

CHMP ASSESSMENT REPORT

FOR

Ellaone

International Nonproprietary Name: ulipristal acetate

Fig. 84

At the time of the CHMP opinion, there were a number of minor unresolved quality issues having no impact on the Benefit/Risk ratio of the product. The applicant gave a letter of Undertaking and committed to resolve these as Follow Up Measures after the opinion, within the agreed timeframe.

2.3. Non-clinical aspects

8

Pharmacology

Ulipristal acetate (17α-Acetoxy-11β-(4-N,N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione, also known as CDB-2914, VA2914, HRP-2000 and RTI-3021-012) is a compound that is derived from 19-norprogesterone. It is a synthetic selective progesterone receptor modulator with antagonistic and partial agonistic effects at the progesterone receptor. It binds the human progesterone, but not the estrogen receptor[3]. Ulipristal acetate prevents progesterone from occupying its receptor, thus the gene transcription normally turned on by progesterone is blocked, and the proteins necessary to begin and maintain pregnancy are not synthesized.

- Primary pharmacodynamics

anti-nidation dynar **termination** th from academic and contract laboratories, often in the form of publications in the scientific literature. The binding of ulipristal acetate to hormonal

"UPA prevents the synthesis of the proteins necessary to begin and maintain pregnancy"

Fig. 85

compete block of gestation was seen at 10 mg/kg and a partial block of gestation at 4 and 8 mg/kg. On days 4, 5 or 6, 32 mg/kg, had no or slight post-coital effect while 64 mg/kg totally blocked gestation in the rabbit.

10

The ability of ulipristal acetate to terminate pregnancies was investigated in the guinea-pig and monkey. Ulipristal, mifepristone and lilopristone were approximately equipotent at the dose levels of 10 and 30 mg/day in terminating pregnancies in guinea-pigs when the animals were treated on days 43 and 44 of gestation. Pregnant long-tailed macaques (5/group) were administered ulipristal acetate 0.5 or 5 mg/kg/day p.o. or 0.5 mg/kg/day i.m. on days 23-26 of gestation. Pregnant animals were assessed by ultrasound pretreatment (day 23) and then monitored on days 26-28, 30, 32, 35, 55, 80, 100, 130 and 145. At 0.5 mg/kg of ulipristal acetate there was no loss of foetuses, while at 5 mg/kg 2/5 foetuses were lost. When using intramuscular administration of 0.5 mg/kg 4/5 foetuses were lost in ulipristal acetate treated animals. In monkeys in which pregnancy continued and which were allowed to deliver normally, there was no evidence of structural or physiological abnormalities in foetuses.

- Secondary pharmacodynamics

Anti-glucocorticoid activity.

unmicronized UPA 50 mg (equivalent to ellaOne) i.m. terminates 80% pregnancies in 100 kg primates (0.5 mg/kg)

Fig. 86

direct action on the endometrium. Despite the small number of women, the study clearly showed that a dose of 200 mg is too high, due to the side effects of prolonged bleeding (two women had a dramatic increase in length of bleeding of 15 and 20 days). The 200 mg dose was omitted from **HRA2914-505** and **HRA2914-506**.

- At mid-follicular phase, doses of 10-100 mg ulipristal acetate caused a suppression of growth of the lead follicle and subsequent delay in ovulation that was greatest at the highest doses (50 and 100 mg), but inhibited luteal phase endometrial maturation similarly at all doses. The threshold for altering endometrial morphology thus appears lower than for inhibition of ovulation.
- At early-luteal phase, none of the given doses (10, 50 and 100 mg) affected the length of the follicular, luteal or overall cycle length during the baseline, treatment or post-treatment menstrual cycle. A significant delay in endometrial maturation occurred in the 50 and 100 mg groups compared to the placebo and 10 mg groups (p=0.02).

The dose of 50 mg unmicronized ulipristal acetate was chosen in the phase II studies, since this was the minimal dose that alters endometrial maturation and induces inhibition of ovulation.

"the threshold to impair endometrial morphology is lower than that required to inhibit ovulation"

Fig. 87

Since the single-dose studies were performed by the NICHD and data were only available from the publications, limited data are available regarding the adverse effects. Ulipristal acetate at 10-50 mg appears to be well tolerated. Post-treatment cycle characteristics were comparable to baseline. The side effects nausea, headache and abdominal pain were noted during 12-weeks administration (**HRA2914-510**), but no mention is made of these side effects after single-dose administration.

Furthermore, a dose-response relation was observed between the ulipristal acetate dose and the presence of cysts in the single-dose **HRA2914-505** study and the multiple-dose **HRA2914-510** study. It is important to know whether these cysts disappear after single-dose administration. In the majority of the subjects this was the case, but not in all women and some women even required surgery. This is discussed further in the Safety section.

Pharmacodynamic interactions with other medicinal products or substances were not studied.

In conclusion, the mechanism of action, as claimed in 5.1 of the SPC *"The primary mechanism of action is thought to be inhibition or delay of ovulation, but alterations to the endometrium may also contribute to the efficacy of the product"*, is sufficiently documented.

Clinical efficacy

- Dose response studies

Dose selection The 50 mg unmicronized ulipristal acetate dose selected for both phase II studies (**HRA2914-507** and **HRA2914-508**) was based on the aforementioned pharmacodynamic studies

Fig. 88

Safety concern	Proposed pharmacovigilance activities	Proposed risk minimisation
Liver effects	- Routine pharmacovigilance - Use of specific report form for spontaneous report - Special attention in PSURs	
Effect on pregnancy maintenance / off-label use as abortifacient	- Routine pharmacovigilance - Use of specific report form for spontaneous report - Special attention in PSURs - Peri/post natal toxicity study in rat (HRA2914-453) - Follow-up of any pregnancy occurring in treated patient of the ongoing phase III study (HRA2914-513) - Observational study within the frame of the Paediatric	Omit any sentence in the SPC and the PL suggesting that the product could be used as an abortifacient. SPC section 4.2: Pregnancy should be excluded before Ellaone is administered. SPC section 4.3: Contraindication : Pregnancy SPC Section 4.6: Ellaone is contra-indicated during an existing or

Risks Minimization Plan - ellaOne potential risks

Fig. 89

pharmacovigilance, special attention will be paid to ovarian cysts in PSURs and ruptured ovarian cysts will be mentioned in section 4.8 of the SPC. Concerning amenorrhoea, besides routine pharmacovigilance, special attention will be paid in PSURs and amenorrhea lasting for more than 60 days will be mentioned in section 4.8 of the SPC.

Off-label use as an abortifacient: The applicant has discussed the following options to monitor intended off-label use of Ellaone:

1. Self-reporting of prescribers,
2. Retrospective survey in Ob/gyn departments among women who are hospitalized for incomplete "spontaneous" abortions or miscarriage
3. Use of prescription registries to identify off-label prescriptions.

It is acknowledged that all these approaches suffer from similar, inevitable limitations (prescribers may not report information about off-label prescriptions). However, the applicant has responded with willingness to undertake the best efforts to evaluate the extent of such practice. In particular, the applicant will attempt to collect data from existing prescription registries on frequency and reasons for Ellaone prescriptions in individual cases, which was endorsed by CHMP. However, in order to be

the possible off-label use as an abortifacient: known monitorable through prescription records..?

Fig. 90

Ellaone prescriptions in individual cases, which was endorsed by CHMP. However, in order to be

meaningful, such measures will have to be implemented only when Ellaone use has reached a certain level of prescription, i.e. not before 1 to 2 years of marketing. The applicant committed to conducting a study using information from prescription registries in countries where it is considered feasible. This will be done after 1-2 years of marketing, depending on the level of Ellaone use. A protocol for such a study should be proposed by the applicant. This issue was resolved by the agreed follow up measures.

Risk Minimization Plan

The CHMP, having considered the data submitted in the application, is of the opinion that no additional risk minimisation activities are required beyond those included in the product information.

HRA-Pharma undertook the duty of never evaluating ellaOne as an abortifacient.. done

Fig. 91

The benefit-risk balance is considered positive.

A risk management plan was submitted. The CHMP, having considered the data submitted, was of the opinion that:

- pharmacovigilance activities in addition to the use of routine pharmacovigilance were needed to investigate further some of the safety concerns.
- no additional risk minimisation activities were required beyond those included in the product information.

Recommendation

Based on the CHMP review of data on quality, safety and efficacy, the CHMP considered by consensus that the risk-benefit balance of Ellaone in the indication of emergency contraception within 120 hours (5 days) of unprotected sexual intercourse or contraceptive failure was favourable and therefore recommended the granting of the marketing authorisation.

ellaOne marketed for EC

Fig. 92

EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

4 December 2014, rev 1
EMA/73099/2015
Committee for Medicinal Products for Human Use (CHMP)

Assessment report

Fig. 93

ellaOne

International non-proprietary name: ulipristal acetate

Procedure No. EMEA/H/C/001027/II/0021

Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

3.4 Even for the minority of women in the EU who do not have access to abortion services delivered by healthcare professionals under medical supervision, ellaOne is an unrealistic option

Women who do not have access to abortion services but want to terminate their pregnancy by themselves find information about their options on the internet (Zamberlin *et al* 2012). Extensive information is readily accessible online about how to perform medication abortion with mifepristone and misoprostol. Although these medicinal products are not readily available in pharmacies, they can be obtained on the Internet.

In contrast, no abortifacient effects have been reported at any dose of UPA or with any duration of therapy in the clinical setting. If women search for methods of abortion they will not be led to any specific information about ellaOne in this regard. In the absence of any clinical data to guide the regimen to be used, a woman could take any number of tablets. The risks of such misuse are deemed low by the MAH.

Fig. 94

(EMA/73099/2015 p. 35/76)

Discussion by the CHMP about second criteria

The risk on off-label use should be considered when the product will be available without a prescription. It is important that the product will be used according to the indication, i.e. within 120 hours after unprotected intercourse.

Therefore during the evaluation process of the ellaOne registration dossier the MAH was requested to study any potential off-label use of ellaOne, in particular during pregnancy possibly as an abortifacient. No clinical studies have been performed with ulipristal acetate as an abortifacient, and it is therefore also unknown whether it is possible to use it for abortion. As to the extrapolations from animal data performed by the MAH to inform the question of abortifacient potency, it was not clear to the CHMP on

ellaOne: no study excludes abortifacient effects

- Of 75 prescribers interviewed in both countries, 20% recalled having prescribed ellaOne more than 5 days after unprotected intercourse (UPI). The main reason given for off-label prescription was uncertainty over the time since UPI.
- 2.7% prescribed more than one dose of ellaOne at once, because of risk of vomiting.

When healthcare professionals were asked (HRA2914-544a) for the reasons of off-label prescription, they unanimously responded that they had never prescribed ellaOne with the intent of terminating an existing pregnancy.

The study demonstrates that off-label prescription of ellaOne for abortion does not happen in the real world, dispelling the concern that existed prior to the approval of the original Marketing Authorisation.

1.2 Selective progesterone receptor modulators are used in a variety of reproductive health indications and are not necessarily perceived as drugs for medication abortion

Fig. 95

(EMA/73099/2015 p. 31/76)

UPA belongs to the family of Selective Progesterone Receptor Modulators (SPRM). The structure of SPRMs is believed to generate a specific conformation of the progesterone receptor resulting in a

“did you ever prescribe ellaOne for abortion?”

“No..”

75, Polish and Svedish, “representative” of all european MD.s

The applicant identified the following safety concerns in the RMP:

Summary of safety concerns	
Important identified risks	None
Important potential risks	• Effects on pregnancy maintenance/off label use • Risk of incomplete abortion and heavy bleeding • Effects on foetus and newborns • Risk of ectopic pregnancy • Concomitant use of CYP3A4 inducers • Liver effects • Delayed menstrual period >60 days / amenorrhea • Ovarian cysts

classification-change from"medicinal product subject to medical prescription" to "medicinal product not subject to medical prescription".

CHMP agrees to remove pregnancy from contraindications ....

The PRAC agreed.

EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA starts review of Esmya for uterine fibroids

Review triggered by cases of liver injury

4 severe liver-toxicity with Esmya
3 transplant e 1 death
(UPA 5mg x 28gg/month)

Fig. 97

EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

1 June 2018
EMA/355940/2018

Esmya: new measures to minimise risk of rare but serious liver injury

EMA concludes review of medicine for uterine fibroids

UPA 5mg x 28gg/month = 140mg/month

highly severe liver damage

Fig. 98

Information for healthcare professionals

- Four cases of serious liver injury leading to hepatic transplantation and additional cases of hepatic injury have been reported in patients treated with Esmya (ulipristal acetate). Although uncertainties around causality remain, the following measures to minimise a possible risk for liver injury will be introduced:
  - Contraindication in patients with underlying liver disorders.
  - Restricted indication in the intermittent treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age: Esmya should only be used in women who are not eligible for surgical treatment. (Esmya continues to be indicated for one course (lasting up to 3 months) of pre-operative treatment for moderate to severe symptoms of uterine fibroids in adult women of reproductive age.)
  - Liver function tests to be performed before starting each treatment course, monthly during the first 2 treatment courses, and thereafter as clinically indicated. Liver testing also to be performed again 2-4 weeks after stopping treatment.

contraindications and warnings for Esmya

no warnings for ellaOne

Fig. 99

- Esmya should not be started if levels of alanine transaminase (ALT) or aspartate aminotransferase (AST) are more than 2 times the upper limit of normal (ULN).
- Treatment should be stopped in patients with ALT or AST levels more than 3 times ULN.

- Healthcare professionals should advise their patients about the signs and symptoms of liver injury and the action to take should they occur. In case of signs or symptoms suggestive of such injury, treatment should be stopped. Patients should be investigated immediately including liver function testing.
- Healthcare professionals prescribing Esmya in the EU will receive a letter with further details once a European Commission decision has been issued.

contraindications and warnings for Esmya

no warnings for ellaOne

Doctors must inform the patients

Fig. 100

EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

4 September 2020
EMA/455818/2020

PRAC recommends revoking marketing authorisation of ulipristal acetate for uterine fibroids

Fig. 101

PRAC - Pharmacovigilance Risk Assessment Committee

A review by EMA's safety committee (PRAC) has confirmed that 5-mg ulipristal acetate (Esmya and generic medicines) used for the treatment of symptoms of uterine fibroids can cause liver injury, including the need for liver transplantation. The PRAC has therefore recommended the revocation of the marketing authorisations of these medicines.

fulminant hepatitis

The PRAC considered all the available evidence in its review, including reported cases of serious liver injury. Patient and healthcare professional representatives, including experts in gynaecology, were also consulted. Since it was not possible to identify which patients were most at risk or measures that could reduce the risk, the PRAC concluded that the risks of these medicines outweighed their benefits and that they should not be marketed in the EU.

The use of 5-mg ulipristal acetate medicines for uterine fibroids had already been suspended as a precautionary measure while awaiting the outcome of this review.

Ulipristal acetate is also authorised as a single-dose medicine for emergency contraception. This recommendation does not affect the single-dose ulipristal acetate emergency contraceptive (ellaOne and other trade names) and there is no concern about liver injury with these medicines.

The PRAC recommendation will now be forwarded to EMA's human medicines committee (CHMP), which will adopt the Agency's opinion.

EMA/455818/2020

post-marketing surveillance

Fig. 102

Clinics and Research in Hepatology and Gastroenterology (2020) 44, e45—e49

Available online at ScienceDirect www.sciencedirect.com

Elsevier Masson France EM|consulte www.em-consulte.com/en

CASE REPORT

Acute liver failure requiring transplantation caused by ulipristal acetate

Post-marketing

Esmya

Lucy Meunier [a,*], Magdalena Meszaros [a], Georges-Philippe Pageaux [a], Jean-Marc Delay [b], Astrid Herrero [c], Véronique Pinzani [d], Hillaire-Buys Dominique [d]

[a] *Liver and Transplantation Unit, University Hospital Montpellier, Montpellier, France*
[b] *Intensive Care Unit, DAR B, University Hospital Montpellier, Montpellier, France*
[c] *Department of General and Liver Transplant Surgery, University Hospital Montpellier, Montpellier, France*
[d] *Department of Medical Pharmacology and Toxicology, CRPV, CHU Montpellier, University Montpellier, 34295 Montpellier, France*

Received 3 February 2020; accepted 14 February 2020
Available online 04 March 2020

Fig. 103

unexpected..?

EMEA/271787/2009 pag. 13

Distribution

Ulipristal acetate was highly bound (96.7-99.5%) to plasma proteins of mouse, rat, rabbit, dog, monkey and human; studies with human protein fractions showed a major role of α1-acid glycoprotein. In addition, ulipristal acetate is also highly bound in blood (4.86% to blood cells and 94.09% to plasma proteins).

Following intravenous and oral administration of ^{14}C-ulipristal acetate to rats and monkeys, radioactivity was widely distributed. In rats, concentrations of radioactivity declined after peak levels, but quantifiable radioactivity levels were still present in all tissues at the final sampling time of 3 days. In addition, in monkeys even after 14 days radioactivity was measurable in all investigated tissues. The liver accounted for the majority of radioactivity in the tissues in the distribution studies in rat and monkey. However, ulipristal acetate also showed a high tissue to plasma ratio in the kidney, clitoris, ovary, uterus, adrenal, fat, uveal tract, pigmented skin and mucosa of the gastro-intestinal tract, indicating accumulation in these organs if the drug is used again a month later. Most likely this has no implications, because ulipristal acetate is given as a single dose, but in repeated dose this could result in toxicity due to accumulation.

- **LIVER: accumulation**
- **TOXICITY from repeated doses**

Known since 2009

Fig. 104

A review by EMA's safety committee (PRAC) has confirmed that 5-mg ulipristal acetate (Esmya and generic medicines) used for the treatment of symptoms of uterine fibroids can cause liver injury, including the need for liver transplantation. The PRAC has therefore recommended the revocation of the marketing authorisations of these medicines.

The PRAC considered all the available evidence in its review, including reported cases of serious liver injury. Patient and healthcare professional representatives, including experts in gynaecology, were also consulted. Since it was not possible to identify which patients were most at risk or measures that could reduce the risk, the PRAC concluded that the risks of these medicines outweighed their benefits and that they should not be marketed in the EU.

The use of 5-mg ulipristal acetate medicines for uterine fibroids had already been suspended as a precautionary measure while awaiting the outcome of this review.

Ulipristal acetate is also authorised as a single-dose medicine for emergency contraception. This recommendation does not affect the single-dose ulipristal acetate emergency contraceptive (ellaOne and other trade names) and there is no concern about liver injury with these medicines.

The PRAC recommendation will now be forwarded to EMA's human medicines committee (CHMP), which will adopt the Agency's opinion.



EMA/455818/2020

NO post-marketing surveillance

Fig. 105

The four criteria mentioned in Article 71 of Directive 2001/83/EC and the European Commission Guideline on changing the classification for the supply of a medicinal product for human use have been considered by the CHMP during the assessment of the variation.

1. Medicinal products shall be subject to medical prescription when they are likely to present a danger either directly or indirectly, even when used correctly, if utilized without medical supervision

ellaOne: NOT subject to medical prescription

administration (HRA2914-554; every 5 days and every 7 days) and a study in adolescents (HRA2914-515) and that the safety profile of ellaOne is comparable with levonorgestrel, the CHMP considered that criteria 1 does not apply to ellaOne.

EMA/73099/2015 page 68

post-marketing surveillance is impossible

Fig. 106

HRA2914-554

Conclusion

The effects of UPA 30 mg administered Q7D or Q5D over 8 weeks demonstrated that following an initial period during which follicular activity was delayed but, following 3 to 6 doses, ovulation occurred in a majority of subjects. When ovulation occurred, physiological and hormonal characteristics indicated no abnormalities. No endometrial hyperplasia or malignancy was reported. No safety issues have been detected, indicating that should the product be used more than once in the

ellaOne: «repeated assumption in the same cycle is as safe as a single dose..»

same cycle, the safety profile is similar to that of established for a single 30 mg dose. Product labelling nevertheless cautions that EC is not to be used repeatedly and encourages women who repeatedly resort to EC to seek counselling and care for regular contraception.

EMA/73099/2015 pages 8-9

Fig. 107

2.2.2.1.2. HRA2914-554

This study shows that ellaOne initially delays follicular activity. However, none of the regimens (every week or every 5 days for 8 consecutive weeks) inhibited ovulation during the whole period of 8 weeks in the majority of subjects. The CHMP agrees that no safety issues are apparent after repeated administration in the same cycle. The endometrial thickness at the end of the study was comparable to baseline luteal values. Non-physiological receptor modulator-associated endometrial changes were observed in one subject in the Q5D group. This is in line with the findings of the Phase III studies of Esmya for the treatment of uterine fibroids in which subjects received daily 5 or 10 mg ulipristal acetate (EPAR Esmya), and is no reason for concern. In the subjects in the Phase III studies of Esmya PAECs were described in approximately 60% of subjects treated with daily ulipristal acetate. PAECs had returned to baseline level when the follow-up biopsy was performed three months after the end of the 3-month treatment period in the Esmya Phase III studies.

Based on this study, the CHMP agrees with the proposal from the MAH to remove the following warning in section 4.4:

"Repeated administration of ellaOne within the same menstrual cycle is not advisable, as safety and efficacy of ellaOne after repeated administration within the same menstrual cycle has not been

removed the warning against repeated assumption in the same cycle

Fig. 108

Clinics and Research in Hepatology and Gastroenterology (2020) 44, e45—e49

Available online at
ScienceDirect
www.sciencedirect.com

Elsevier Masson France
EM|consulte
www.em-consulte.com/en

CASE REPORT

Acute liver failure requiring transplantation caused by ulipristal acetate

Post-marketing

Esmya

Lucy Meunier [a,*], Magdalena Meszaros [a], Georges-Philippe Pageaux [a], Jean-Marc Delay [b], Astrid Herrero [c], Véronique Pinzani [d], Hillaire-Buys Dominique [d]

[a] *Liver and Transplantation Unit, University Hospital Montpellier, Montpellier, France*
[b] *Intensive Care Unit, DAR B, University Hospital Montpellier, Montpellier, France*
[c] *Department of General and Liver Transplant Surgery, University Hospital Montpellier, Montpellier, France*
[d] *Department of Medical Pharmacology and Toxicology, CRPV, CHU Montpellier, University Montpellier, 34295 Montpellier, France*

Received 3 February 2020; accepted 14 February 2020
Available online 04 March 2020

Fig. 109

Table 1 Other cases with ulipristal and hepatic transplant.

Case ID	Country code age (yrs)	MedDRA SMQ PT Delay on ulipristal	Relevant medical history	Past/concomitant medication	Case description
Case 1	PT 55	Hepatic failure 109 days on Esmya®	Non-smoker, No alcohol abuse, No drug allergy, Hepatitis A at age 18, labs within normal range	Esmya: 11 Jul 2014–24 Oct 2014. Amoxicillin in Jan, Cefuroxime 750 mg from 24 oct 2014 for Klebsiella pneumoniae for 2 days (discontinued) Sleep and Go dietary supplement in Oct 2014 for 2 days	On 2nd day of treatment: fatigue, asthenia, anorexia and post-prandial fullness, no jaundice. 27 Oct-1 Nov 2014: hospitalised due to acute hepatitis. Esmya discontinued. On 7 Nov 2014 ultrasound: probable hepatic steatosis. Serology: negative for hepatitis A, B, C, E, HIV virus ANA autoimmunity, anti-ds-DNA antibodies, anti-LKM antibodies, AMA, ASMA and c-ANCA negatives; On 12 Dec 2014: liver transplant
Case 2	FR 45	Hepatocellular injury, Drug-induced liver injury 3–26 days on Esmya®	BMI: 28.1, EBV, CMV, Herpes virus 6a and 6b in genome, No herbal products, No other drugs, No holidays abroad, No alcohol abuse	Esmya: 28 Jun 2017–23 Jul 2017 No other medication	On 3rd day: asthenia, nausea and vomiting. On 23 Jul 2017: jaundice. Esmya discontinued. Liver biopsy non-typical for drug-induced hepatitis. Serology negative for hepatitis A, B, C, E, CMV, HIV virus. On 26 Jul 2017 hospitalisation PCR negative for herpes simp

ellaOne

half tablet - 4 tablets

15 mg **120 mg**

UPA-ellaOne: the bolus is 6 times higher than in Esmya

Fig. 110